|
1
|
Bilhim T, Vasco Costa N, Torres D, Akış S, Alves M, Papoila AL. Comparing embolic particles for prostatic artery embolization to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. Eur Radiol 2025; 35:1057-1066. [PMID: 39107451 DOI: 10.1007/s00330-024-10998-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 07/04/2024] [Accepted: 07/18/2024] [Indexed: 02/01/2025]
Abstract
PURPOSE Compare the safety and efficacy of polyvinyl alcohol particles (PVA) versus trisacryl gelatin microspheres (Embospheres) versus hydrogel microspheres coated with polyzene-F (Embozenes) for prostatic artery embolization (PAE) to treat patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS A single-center prospective cohort study from 2019 to 2023, including patients with international prostate symptom score (IPSS) ≥ 15 and/or quality of life score (QoL) ≥ 4. Allocation to embolic agents was performed chronologically: 100-300 µm PVA (n = 53), followed by 300-500 µm Embospheres (n = 50), and finally, 400 µm Embozenes (n = 50). All patients were evaluated at baseline and at 1 and 6 months after PAE with IPSS/QoL; peak urinary flow rate, post-void residual volume, and prostate volume with ultrasound and prostate-specific antigen. Adverse events and the need for prostatic re-interventions were assessed. RESULTS There were no significant baseline differences between the three groups except for patient age (62.5 years PVA; 66.1 years Embospheres and 66.6 years Embozenes; p = 0.019). There were no major adverse events and no differences between groups regarding minor adverse events. All outcome measures improved significantly from baseline, with no significant differences between groups. Mean ± standard deviation IPSS/QoL improvement at 6 months: -10.7 ± 7.9/-2.2 ± 1.7 PVA; -10.4 ± 7.3/-2.0 ± 1.5 Embospheres; -10.4 ± 7.0/-2.2 ± 1.6 Embozenes (p = 0.987). Re-intervention rates after 6 months: 9% (n = 5/53) PVA; 14% (n = 7/50) Embospheres; 8% (n = 4/50) Embozenes (p = 0.591). CONCLUSIONS PAE with PVA particles, Embospheres, and Embozenes is equally safe and effective in treating BPH-related lower urinary tract symptoms. CLINICAL RELEVANCE STATEMENT This is the first prospective study showing equivalence between the most frequently used embolic agents for prostatic artery embolization. KEY POINTS Different particles can be used interchangeably for prostatic artery embolization. The improvements in measured metrics were the same between groups, with no differences in adverse events. The need for prostatic medication and re-intervention rates were the same at 1 and 6 months after embolization.
Collapse
Affiliation(s)
- Tiago Bilhim
- Interventional Radiology Unit, Curry Cabral Hospital, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal.
- Interventional Radiology Unit, SAMS Hospital, Lisbon, Portugal.
| | - Nuno Vasco Costa
- Interventional Radiology Unit, Curry Cabral Hospital, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal
- Interventional Radiology Unit, SAMS Hospital, Lisbon, Portugal
| | - Daniel Torres
- Interventional Radiology Unit, Curry Cabral Hospital, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal
- Interventional Radiology Unit, SAMS Hospital, Lisbon, Portugal
| | - Serhat Akış
- Department of Radiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Türkiye
| | - Marta Alves
- Epidemiology and Statistics Unit, Research Center, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal
- Nova Medical School|Faculdade de Ciências Médicas da UNL, and Centro de Estatística e Aplicações da Universidade de Lisboa (CEAUL), Lisboa, Portugal
| | - Ana Luisa Papoila
- Epidemiology and Statistics Unit, Research Center, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal
- Nova Medical School|Faculdade de Ciências Médicas da UNL, and Centro de Estatística e Aplicações da Universidade de Lisboa (CEAUL), Lisboa, Portugal
| |
Collapse
|
|
2
|
Bamshad D, Sanghvi J, Galla N, Geffner A, Menon K, Bishay V, Shilo D, Garcia-Reyes K, Lookstein R, Rastinehad A, Fischman A. Early Outcomes of Prostatic Artery Embolization using n-Butyl Cyanoacrylate Liquid Embolic Agent: A Safety and Feasibility Study. J Vasc Interv Radiol 2024; 35:1855-1861. [PMID: 39074551 DOI: 10.1016/j.jvir.2024.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 06/17/2024] [Accepted: 07/19/2024] [Indexed: 07/31/2024] Open
Abstract
This retrospective study evaluated the feasibility, safety, and short-term effectiveness of prostatic artery embolization (PAE) using n-butyl cyanoacrylate (nBCA) glue embolization in 244 patients from June 2022 through May 2024. Technical success, defined as bilateral glue embolization, was achieved in 95% of cases. The median fluoroscopy time was 22.2 minutes (interquartile range [IQR], 17.1-30.0 minutes), and the median air kerma was 753 mGy (IQR, 417-1,559 mGy). Compared with baseline, statistically significant improvements were observed at 7.1 weeks for the International Prostate Symptom Score (9.5 [SD ± 6.0] vs 20.5 [SD ± 6.7]; P < .01), quality of life (1.8 [SD ± 1.5] vs 4.0 [SD ± 1.1]; P < .01), Qmax (10.4 mL/s [SD ± 6.3] vs 6.1 mL/s [SD ± 2.5]; P < .01), and prostate grand volume at 6 months (113.3 mL [SD ± 69.3] vs 156.6 mL [SD ± 104.6]; P < .01). These results demonstrate the use of nBCA for PAE as a technically feasible and safe option with excellent short-term outcomes.
Collapse
Affiliation(s)
- David Bamshad
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
| | - Jay Sanghvi
- Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Naveen Galla
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Adam Geffner
- Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Kartikeya Menon
- Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Vivian Bishay
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Dan Shilo
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Kirema Garcia-Reyes
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Robert Lookstein
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Ardeshir Rastinehad
- The Smith Institute for Urology at Lenox Hill, Northwell Health, New York, New York
| | - Aaron Fischman
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
|
3
|
Sapoval MR, Bhatia S, Déan C, Rampoldi A, Carnevale FC, Bent C, Tapping CR, Bongiovanni S, Taylor J, Brower JS, Rush M, McWilliams JP, Little MW. Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study. Cardiovasc Intervent Radiol 2024; 47:1515-1524. [PMID: 39230672 PMCID: PMC11541243 DOI: 10.1007/s00270-024-03802-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 06/25/2024] [Indexed: 09/05/2024]
Abstract
PURPOSE To describe clinical outcomes among patients with benign prostatic hyperplasia (BPH) 24 months following prostatic artery embolization (PAE). MATERIALS AND METHODS This was an international, multicenter, prospective trial of males with BPH with lower urinary tract symptoms (LUTS) or acute urinary retention (AUR) treated with PAE. The primary outcome was the 12 month change in the International Prostate Symptom Score (IPSS) for patients referred for bothersome LUTS, or urinary catheter independence for patients treated for AUR. Secondary outcome measures included changes in IPSS at 3 and 24 months, changes in quality of life (QoL), changes in the Sexual Health Inventory for Men (SHIM) questionnaire, technical success rate, and adverse events (AEs). Data were summarized using descriptive statistics. RESULTS Four hundred seventy-eight consecutive patients underwent PAE (bothersome LUTS: N = 405; AUR: N = 73), mean age was 70 years. For patients treated for bothersome LUTS, mean total IPSS at baseline was 21.8 and decreased to 9.3, 10.6, and 11.2 at 3, 12, and 24 months following PAE, respectively (all p < 0.001); QoL at baseline was 4.7 and decreased to 2.0, 2.1, and 2.3 at 3, 12, and 24 months, respectively (all p < 0.001). The mean SHIM score at baseline and 12 months following PAE was 13.8 and 13.9, respectively. Of the 73 patients treated for AUR, 48 (65.8%) had their indwelling catheter removed within 3 months of PAE and remained catheter free at 24 months. Fifty-five patients (11.5%) experienced ≥ 1 AE and 10 (2.1%) experienced a serious AE. CONCLUSION PAE is a safe and effective treatment for symptomatic BPH and LUTS. Level of Evidence Level 3 Trial registration ClinicalTrials.gov NCT03527589.
Collapse
Affiliation(s)
- Marc R Sapoval
- Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015, Paris, France.
| | - Shivank Bhatia
- Department of Interventional Radiology, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - Carole Déan
- Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015, Paris, France
| | - Antonio Rampoldi
- Department of Interventional Radiology, Ospedale Niguarda Ca' Granda, Milan, Italy
| | - Francisco César Carnevale
- Department of Radiology, Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
| | - Clare Bent
- Department of Interventional Radiology, Royal Bournemouth and Christchurch Hospital, Bournemouth, UK
| | | | - Simone Bongiovanni
- Department of Radiology, Azienda Ospedaliera S. Croce E Carle, Cuneo, Italy
| | - Jeremy Taylor
- Department of Interventional Radiology, Frimley Park Hospital, Surrey, UK
| | - Jayson S Brower
- Department of Radiology, Providence Sacred Heart, Spokane, WA, USA
| | - Michael Rush
- Holy Cross South Florida Medical Imaging, Fort Lauderdale, FL, USA
| | - Justin P McWilliams
- Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Mark W Little
- University Department of Radiology, Royal Berkshire Hospital, Reading, UK
| |
Collapse
|
|
4
|
Alizadeh LS, Radek D, Booz C, Verloh N, Yel I, Koch V, Martin S, Gruenewald LD, Dimitrova M, Vogl TJ. Prostatic Artery Embolization: Lessons From 551 Procedures at a Single-Center. Acad Radiol 2024; 31:4519-4527. [PMID: 38862346 DOI: 10.1016/j.acra.2024.05.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 05/21/2024] [Accepted: 05/21/2024] [Indexed: 06/13/2024]
Abstract
RATIONALE AND OBJECTIVES This retrospective study evaluates the efficacy and safety of Prostatic Artery Embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) over five years at a single center, conducted by an experienced interventional radiologist. MATERIALS AND METHODS We analyzed 551 PAE interventions from January 2019 to July 2023. Key metrics included patient demographics, procedural details (radiation exposure, particle size), complication rates, pre- and post-interventional prostatic volume (PV), Prostate-specific Antigen (PSA) levels, International Prostate Symptom Score (IPSS), Quality of Life (QoL) scores and International Index of Erectile Function (IIEF) scores. We assessed data normality, performed group and paired sample comparisons, and evaluated correlations. RESULTS For 551 men, the average patient age was 68.81 ± 8.61 years undergoing bilateral embolization. The particle size predominantly used was 100-300 µm (n = 441). PAE lead to significant (p < .001) reduction of both PV (-9.67 ± 14.52 mL) and PSA level (-2,65 ± 1.56 ng/mL) between pre- and three months after PAE. Substantial improvement were observed for IPSS (-9 points) and QoL scores (-2 points), with stable IIEF scores. Only minor complications (n = 16) were reported, and no major complications were observed. Between the first PAE in 2019 and the routinely performed PAE in 2023 significant (p < .0001) reductions in fluoroscopy (-25.2%), and procedural times (-26.1%) were observed. CONCLUSION In conclusion, PAE is a safe and effective treatment for BPH, offering significant improvements in lower urinary tract symptoms (LUTS) and QoL while maintaining sexual function.
Collapse
Affiliation(s)
- Leona S Alizadeh
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany.
| | - David Radek
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Christian Booz
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Niklas Verloh
- Department of Diagnostic and Interventional Radiology, University Hospital Freiburg, Germany
| | - Ibrahim Yel
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Vitali Koch
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Simon Martin
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Leon D Gruenewald
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Mirela Dimitrova
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany; Division of Experimental Imaging, Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| | - Thomas J Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Germany
| |
Collapse
|
|
5
|
Cusumano LR, Rink JS, Callese T, Maehara CK, Mathevosian S, Quirk M, Plotnik A, McWilliams JP. Cost Comparison of Prostatic Artery Embolization Between In-Hospital and Outpatient-Based Lab Settings. Cureus 2024; 16:e67433. [PMID: 39310461 PMCID: PMC11415309 DOI: 10.7759/cureus.67433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/21/2024] [Indexed: 09/25/2024] Open
Abstract
Purpose This study aimed to determine the costs associated with prostatic artery embolization (PAE) performed in hospital and outpatient-based lab (OBL) settings. Methods Procedures were performed in similarly equipped procedure suites located within a tertiary hospital or OBL. Time-driven activity-based costing (TDABC) was utilized to calculate procedural costs incurred by the institution. Process maps were created describing personnel, space, equipment, and materials. The time duration of each procedural step was recorded independently by a nurse caring for the patient at the time of the procedure, and mean values were included in our model. Using institutional and publicly available financial data, costs, and capacity cost rates were determined. Results Thirty-seven PAE procedures met inclusion criteria with a mean patient age of 70.4 (+/- 6.7) years and a mean prostate gland size of 129.7 (+/-56.4) cc. Twenty-six procedures were performed within the hospital setting, and 11 procedures were performed within the OBL. Reduction in International Prostate Symptom Score (IPSS) was not significantly different following hospital and OBL procedures (57.2% vs. 82.4%, P = 0.0796). Mean procedural time was not significantly different between the hospital and OBL settings (136.6 vs. 147.3 minutes, P = 0.1893). However, the duration between admission and discharge was significantly longer for procedures performed in a hospital (468.8 vs. 325.4 minutes, P <0.0001). Total costs for hospital-based procedures were marginally higher ($3,858.28 vs. $3,642.67). Conclusion Total PAE cost was similar between the hospital and OBL settings. However, longer periprocedural times for hospital-based procedures and differences in reimbursement may favor the performance of PAE in an OBL setting.
Collapse
Affiliation(s)
- Lucas R Cusumano
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| | - Johann S Rink
- Department of Clinical Radiology and Nuclear Medicine, Mannheim University Medical Centre, Mannheim, DEU
| | - Tyler Callese
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| | - Cleo K Maehara
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA
| | - Sipan Mathevosian
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| | - Matthew Quirk
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| | - Adam Plotnik
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| | - Justin P McWilliams
- Department of Radiological Sciences, David Geffen School of Medicine at University of California, Los Angeles, USA
| |
Collapse
|
|
6
|
Wise R, Fu H, Tapping CR. Prostate volume: does it predict patient outcomes following prostate artery embolisation? A retrospective cohort study. CVIR Endovasc 2024; 7:51. [PMID: 38935182 PMCID: PMC11211285 DOI: 10.1186/s42155-024-00464-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Accepted: 06/11/2024] [Indexed: 06/28/2024] Open
Abstract
Prostate artery embolisation (PAE) is a minimally invasive procedure commonly performed to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. International Prostate Symptom Score (IPSS) is a validated patient questionnaire quantifying LUTS and is used for patient selection for PAE, but it is largely subjective. Prostate volume is an easily estimated objective parameter across multiple imaging modalities. No strict threshold of prostate volume is established as a selection criterion for PAE, but it is generally accepted that prostate volume should be over 40 to 50 mL.We looked at a sample of 65 cases performed at a large teaching hospital between 2017 and 2019 with a minimum of four years follow up. Embospheres between 100 to 500 microns were injected into the prostatic arteries bilaterally (if technically feasible). A 'bullet shape' model was used to estimate prostatic volume from initial CT. N = 13 had an estimated volume < 51 mL (range 31-50 mL). IPSS before and at 3 months post-procedure were collected.80% of patients indicated a beneficial response to PAE (IPSS improvement > 5). 23% of patients required further PAE procedure or surgery. No major complications were recorded. The mean change in IPSS under 51 mL compared to over 51 mL cohort was 10.2 versus 11 (standard deviation 7.5 versus 7.3) (p = 0.44, 2 tailed Student's T-test).There was no statistically significant difference in the IPSS improvement or outcome of small volume prostates under 51 mL compared to large volume. Our results suggest that prostate volume should not be used to exclude patients for PAE.
Collapse
Affiliation(s)
- Robert Wise
- Department of Radiology, Oxford University Hospitals NHS Foundation Trust John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, United Kingdom.
| | - Howell Fu
- Department of Radiology, Oxford University Hospitals NHS Foundation Trust John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, United Kingdom
| | - Charles Ross Tapping
- Department of Radiology, Oxford University Hospitals NHS Foundation Trust John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, United Kingdom
| |
Collapse
|
|
7
|
Netsch C, Gross AJ, Herrmann TR, Herrmann J, Becker B. [Minimally-Invasive Surgical Techniques (MIST): Shedding Light on the Mist]. Aktuelle Urol 2024; 55:219-227. [PMID: 38547919 DOI: 10.1055/a-2269-1280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2024]
Abstract
As life expectancy increases and there is growing demand for BPH treatments, innovative technologies have been developed, allowing for swift recovery, symptom relief, low complication rates, and the possibility of performing procedures on an outpatient basis, often under local anaesthesia. This review aims to describe the outcomes of newly developed minimally-invasive surgical therapies (MIST) for BPH treatment in terms of functional voiding parameters and sexual function. These therapies are categorized into primarily ablative (Aquablation [Aquabeam]), non-ablative (Prostatic Urethral Lift (PUL, Urolift), temporary implantable devices [iTind]), and secondarily ablative procedures (convective water vapor ablation, Rezum, Prostate Artery Embolization [PAE]). All MIST technologies have advanced the medical care of patients with BPH while preserving ejaculation. However, there is a shortage of long-term data specifically addressing re-intervention rates and the preservation of functional voiding parameters. Although there is promising data from regulatory trials and randomized studies, all MIST therapies are potentially associated with severe complications. Patients considering such methods must be thoroughly informed about their inferiority compared with established transurethral procedures like TUR-P and enucleation.
Collapse
Affiliation(s)
| | - Andreas J Gross
- Abteilung für Urologie, Asklepios Klinik Barmbek, Hamburg, Germany
| | | | - Jonas Herrmann
- Urologie und Urochirurgie, Universitätsklinikum Mannheim, Mannheim, Germany
| | - Benedikt Becker
- Abteilung für Urologie, Asklepios Klinik Barmbek, Hamburg, Germany
| |
Collapse
|
|
8
|
Ini’ C, Vasile T, Foti PV, Timpanaro C, Castiglione DG, Libra F, Falsaperla D, Tiralongo F, Giurazza F, Mosconi C, David E, Palmucci S, Lavalle S, Venturini M, Basile A. Prostate Artery Embolization as Minimally Invasive Treatment for Benign Prostatic Hyperplasia: An Updated Systematic Review. J Clin Med 2024; 13:2530. [PMID: 38731058 PMCID: PMC11085005 DOI: 10.3390/jcm13092530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Revised: 04/09/2024] [Accepted: 04/22/2024] [Indexed: 05/13/2024] Open
Abstract
Background/Objectives: Benign prostatic hyperplasia (BPH) has a significant impact on the quality of life of symptomatic patients. In patients manifesting lower urinary tract symptoms (LUTS), prostatic arterial embolization (PAE) has become a topic of interest in recent years. The purpose of this systematic review is to analyze and review techniques and clinical outcomes of patients who underwent endovascular treatment of BPH, with a special focus on the comparison of surgical and endovascular procedures. Methods: Through the major scientific databases, 1225 articles were selected from the initial research utilizing specific keywords and medical subject headings. Based on the inclusion and exclusion criteria established for selecting relevant studies for our purposes, the systematic analysis of the literature was conducted on a total of seven articles. Results: We collected data on 718 male patients (408 patients underwent PAE and 310 received TURP). The technical success rate varied from 86% to 100% for TAE and was 100% for TURP. During a 12-month follow-up period, both PAE and TURP were comparable on the reduction in IPSS and QoL questionnaire, while TURP showed significant improvements in Qmax and in the reduction in prostate volume. Length and cost of hospitalization were lower for PAE. Complication and adverse events rates were higher in the TURP group rather than in the PAE group (60.6% vs. 35.5%). Conclusions: Prostatic artery embolization represents an emerging minimally invasive procedure for BPH. According to previously released clinical studies, quality-of-life and urological symptom scores of the PAE group were comparable to those of the TURP group. Our research strengthens the evidence supporting the effectiveness and safety of PAE as a therapy for LUTS related to BPH.
Collapse
Affiliation(s)
- Corrado Ini’
- Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (D.G.C.); (F.L.); (D.F.); (F.T.)
| | - Tiziana Vasile
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
| | - Pietro Valerio Foti
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
- NANOMED-Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, 95125 Catania, Italy
- Centro di Ricerca Multidisciplinare “Chirurgia delle Sindromi Malformative Complesse della Transizione e dell’Età Adulta” (ChiSMaCoTA), Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy
| | - Concetta Timpanaro
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
| | - Davide Giuseppe Castiglione
- Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (D.G.C.); (F.L.); (D.F.); (F.T.)
| | - Federica Libra
- Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (D.G.C.); (F.L.); (D.F.); (F.T.)
| | - Daniele Falsaperla
- Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (D.G.C.); (F.L.); (D.F.); (F.T.)
| | - Francesco Tiralongo
- Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (D.G.C.); (F.L.); (D.F.); (F.T.)
| | - Francesco Giurazza
- Vascular and Interventional Radiology Department, Cardarelli Hospital, Via A. Cardarelli 9, 80131 Naples, Italy;
| | - Cristina Mosconi
- Department of Radiology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, 40138 Bologna, Italy;
| | - Emanuele David
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
| | - Stefano Palmucci
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
| | - Salvatore Lavalle
- Dipartimento di Medicina e Chirurgia, Università degli Studi di Enna “Kore” Cittadella Universitaria, 94100 Enna, Italy;
| | - Massimo Venturini
- Diagnostic and Interventional Radiology Department, Circolo Hospital, Insubria University, 21100 Varese, Italy;
| | - Antonio Basile
- Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia”—Radiology I Unit, University Hospital Policlinico “G. Rodolico-San Marco”, Via Santa Sofia 78, 95123 Catania, Italy; (T.V.); (P.V.F.); (C.T.); (E.D.); (S.P.); (A.B.)
| |
Collapse
|
|
9
|
Boschheidgen M, Ullrich T, Al-Monajjed R, Ziayee F, Michalski R, Steuwe A, Minko P, Albers P, Antoch G, Schimmöller L. Value of magnetic resonance angiography before prostatic artery embolization for intervention planning. Sci Rep 2024; 14:7758. [PMID: 38565890 PMCID: PMC10987590 DOI: 10.1038/s41598-024-58207-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 03/26/2024] [Indexed: 04/04/2024] Open
Abstract
Knowledge about anatomical details seems to facilitate the procedure and planning of prostatic artery embolization (PAE) in patients with symptomatic benign prostatic hyperplasia (BPS). The aim of our study was the pre-interventional visualization of the prostatic artery (PA) with MRA and the correlation of iliac elongation and bifurcation angles with technical success of PAE and technical parameters. MRA data of patients with PAE were analysed retrospectively regarding PA visibility, PA type, vessel elongation, and defined angles were correlated with intervention time, fluoroscopy time, dose area product (DAP), cumulative air kerma (CAK), contrast media (CM) dose and technical success of embolization. T-test, ANOVA, Pearson correlation, and Kruskal-Wallis test was applied for statistical analysis. Between April 2018 and March 2021, a total of 78 patients were included. MRA identified the PA origin in 126 of 147 cases (accuracy 86%). Vessel elongation affected time for catheterization of right PA (p = 0.02), fluoroscopy time (p = 0.05), and CM dose (p = 0.02) significantly. Moderate correlation was observed for iliac bifurcation angles with DAP (r = 0.30 left; r = 0.34 right; p = 0.01) and CAK (r = 0.32 left; r = 0.36 right; p = 0.01) on both sides. Comparing the first half and second half of patients, median intervention time (125 vs. 105 min.) and number of iliac CBCT could be reduced (p < 0.001). We conclude that MRA could depict exact pelvic artery configuration, identify PA origin, and might obviate iliac CBCT. Vessel elongation of pelvic arteries increased intervention time and contrast media dose while the PA origin had no significant influence on intervention time and/or technical success.
Collapse
Affiliation(s)
- Matthias Boschheidgen
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Tim Ullrich
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Rouvier Al-Monajjed
- Department of Urology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Farid Ziayee
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Rene Michalski
- Department of Urology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Andrea Steuwe
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Peter Minko
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Peter Albers
- Department of Urology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Gerald Antoch
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany
| | - Lars Schimmöller
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstr. 5, 40225, Dusseldorf, Germany.
- Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
| |
Collapse
|
|
10
|
Ayyagari R, Rahman SZ, Grizzard K, Mustafa A, Staib LH, Makkia RS, Bhatia S, Bilhim T, Carnevale FC, Davis C, Fischman A, Isaacson A, McClure T, McWilliams J, Nutting C, Richardson A, Salem R, Sapoval M, Yu H. Multicenter Quantification of Radiation Exposure and Associated Risks for Prostatic Artery Embolization in 1476 Patients. Radiology 2024; 310:e231877. [PMID: 38441098 DOI: 10.1148/radiol.231877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2024]
Abstract
Background Prostatic artery embolization (PAE) is a safe, minimally invasive angiographic procedure that effectively treats benign prostatic hyperplasia; however, PAE-related patient radiation exposure and associated risks are not completely understood. Purpose To quantify radiation dose and assess radiation-related adverse events in patients who underwent PAE at multiple centers. Materials and Methods This retrospective study included patients undergoing PAE for any indication performed by experienced operators at 10 high-volume international centers from January 2014 to May 2021. Patient characteristics, procedural and radiation dose data, and radiation-related adverse events were collected. Procedural radiation effective doses were calculated by multiplying kerma-area product values by an established conversion factor for abdominopelvic fluoroscopy-guided procedures. Relationships between cumulative air kerma (CAK) or effective dose and patient body mass index (BMI), fluoroscopy time, or radiation field area were assessed with linear regression. Differences in radiation dose stemming from radiopaque prostheses or fluoroscopy unit type were assessed using two-sample t tests and Wilcoxon rank sum tests. Results A total of 1476 patients (mean age, 69.9 years ± 9.0 [SD]) were included, of whom 1345 (91.1%) and 131 (8.9%) underwent the procedure with fixed interventional or mobile fluoroscopy units, respectively. Median procedure effective dose was 17.8 mSv for fixed interventional units and 12.3 mSv for mobile units. CAK and effective dose both correlated positively with BMI (R2 = 0.15 and 0.17; P < .001) and fluoroscopy time (R2 = 0.16 and 0.08; P < .001). No radiation-related 90-day adverse events were reported. Patients with radiopaque implants versus those without implants had higher median CAK (1452 mGy [range, 900-2685 mGy] vs 1177 mGy [range, 700-1959 mGy], respectively; P = .01). Median effective dose was lower for mobile than for fixed interventional systems (12.3 mSv [range, 8.5-22.0 mSv] vs 20.4 mSv [range, 13.8-30.6 mSv], respectively; P < .001). Conclusion Patients who underwent PAE performed with fixed interventional or mobile fluoroscopy units were exposed to a median effective radiation dose of 17.8 mSv or 12.3 mSv, respectively. No radiation-related adverse events at 90 days were reported. © RSNA, 2024 See also the editorial by Mahesh in this issue.
Collapse
Affiliation(s)
- Raj Ayyagari
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Saumik Z Rahman
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Kevin Grizzard
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Adel Mustafa
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Lawrence H Staib
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Rasha S Makkia
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Shivank Bhatia
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Tiago Bilhim
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Francisco C Carnevale
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Clifford Davis
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Aaron Fischman
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Ari Isaacson
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Timothy McClure
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Justin McWilliams
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Charles Nutting
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Andrew Richardson
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Riad Salem
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Marc Sapoval
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| | - Hyeon Yu
- From the Boston Medical Center, 75 Albany Street, Boston, MA 02118 (R.A.); Yale University School of Medicine, New Haven, Conn (S.Z.R., K.G., A.M., L.H.S., R.S.M.); University of Miami Miller School of Medicine, Miami, Fla (S.B., A.R.); Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (T.B.); Universidade de São Paulo Faculdade de Medicina, São Paulo, Brazil (F.C.C.); University of South Florida Morsani College of Medicine, Tampa, Fla (C.D.); Icahn School of Medicine at Mount Sinai, New York, NY (A.F.); Prostate Centers Raleigh, Raleigh, NC (A.I.); Weill Cornell Medical College, New York, NY (T.M.); University of California Los Angeles David Geffen School of Medicine, Los Angeles, Calif (J.M.); Endovascular Consultants of Colorado, Lone Tree, Colo (C.N.); Northwestern University Feinberg School of Medicine, Evanston, Ill (R.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France (M.S.); and The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC (H.Y.)
| |
Collapse
|
|
11
|
Wang RL, Lin FF, Ruan DD, Li SJ, Zhou YF, Luo JW, Fang ZT, Tang Y. A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization. Abdom Radiol (NY) 2024; 49:927-938. [PMID: 38158423 DOI: 10.1007/s00261-023-04131-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/08/2023] [Accepted: 11/12/2023] [Indexed: 01/03/2024]
Abstract
PURPOSE To analyze the correlation between the prostate necrosis rate at 1-month after prostatic artery embolization (PAE) and the clinical efficacy at 1-year after PAE, and to explore potential predictors of clinical success after PAE for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). METHODS The prostate magnetic resonance imaging data at 1-month after PAE were imported into 3D Slicer software for calculating the prostate necrosis rate and thus analyzing the relationship between the prostate necrosis rate at 1-month after PAE and the efficacy score ratio at 1-year after PAE. The 151 patients with PAE technical success were divided into a clinical success group (n = 126) and a clinical failure group (n = 25). Independent predictors of clinical success after PAE were analyzed by multifactorial logistic regression, and the predictive performance of each factor was evaluated by applying the receiver operating characteristic curve and the area under the curve (AUC). RESULTS There was a linear negative correlation between the prostate necrosis rate at 1-month after PAE and the efficacy score ratio at 1-year after surgery (P < 0.001). In the clinical success group, both the initial prostate volume (PV) and the prostate necrosis rate at 1-month after PAE were significantly higher than in the clinical failure group (P < 0.001), and acute urinary retention (AUR) and adenomatous-dominant BPH were also associated with clinical success (P < 0.05). Multifactorial logistic regression analysis revealed that larger initial PV, a higher prostate necrosis rate at 1-month after surgery, and AUR were independent predictors of clinical success after PAE. The AUC values for these three indicators and their combination were 0.720, 0.928, 0.599, and 0.951, respectively, in which the prostate necrosis rate at 1-month after PAE demonstrating a high predictive value. CONCLUSION The higher the prostate necrosis rate at 1-month after PAE, the better the clinical efficacy at 1-year after PAE is likely to be, and the prostate necrosis rate at 1-month after PAE is expected to become a predictor of clinical success after PAE.
Collapse
Affiliation(s)
- Ruo-Li Wang
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou, 350001, China
| | - Fang-Fang Lin
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China
- Radiology Department, Fujian Provincial Hospital, Fuzhou, 350001, China
| | - Dan-Dan Ruan
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China
| | - Shi-Jie Li
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China
| | - Yan-Feng Zhou
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China
- Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, 350001, China
| | - Jie-Wei Luo
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
| | - Zhu-Ting Fang
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
- Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, 350001, China.
| | - Yi Tang
- Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
- Department of Interventional Radiology, Fujian Provincial Hospital, Fuzhou, 350001, China.
| |
Collapse
|
|
12
|
Salem J, Becher KF, Bschleipfer T, Dreikorn K, Höfner K, Madersbacher S, Magistro G, Muschter R, Oelke M, Reich O, Rieken M, Schönburg S, Abt D. [Minimally invasive treatment of benign prostatic hyperplasia : The German S2e guideline 2023-part 4]. UROLOGIE (HEIDELBERG, GERMANY) 2024; 63:58-66. [PMID: 38193989 DOI: 10.1007/s00120-023-02249-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/22/2023] [Indexed: 01/10/2024]
Abstract
BACKGROUND Lower urinary tract symptoms suggestive for benign prostatic obstruction (LUTS/BPO) are one of the most frequent diseases in men and can have a significant impact on quality of life. Instrumental therapies are common, and many patients seek minimally invasive treatment options. OBJECTIVE Presentation and evidence-based evaluation of the minimally invasive therapy for benign prostatic syndrome. MATERIALS AND METHODS Summary and overview of chapters 11-13 on minimally invasive therapies for LUTS/BPO of the current long version of the German S2e guideline. RESULTS In case of absolute indication for surgery or after unsatisfactory or undesired medical therapy, minimally invasive treatments such as UroLift® (Neotract Inc., Pleasanton, CA, USA), Rezῡm™ (Boston Scientific, Malborough, MA, USA), iTIND™ (Olympus America Inc., Westborough, MA, USA), and prostatic artery embolization (PAE) can be considered. These indirect/delayed ablative therapies offer lower morbidity and the possibility of performing them under local anesthesia, but they are inferior to direct ablative/resective techniques in terms of effectiveness and sustainability. CONCLUSIONS The updated German S2e guideline summarizes evidence-based recommendations for new minimally invasive therapies for LUTS/BPO, which present alternative treatment options for selected patients.
Collapse
Affiliation(s)
- Johannes Salem
- CUROS urologisches Zentrum, Klinik LINKS VOM RHEIN, Schillingsrotterstr. 39-41, 50996, Köln, Deutschland.
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Brandenburg a.d. Havel, MHB Brandenburg Theodor Fontane, Brandenburg a.d. Havel, Deutschland.
| | - Klaus F Becher
- Klinik für Rehabilitation, Klinik Wartenberg Professor Dr. Selmair GmbH & Co. KG, Wartenberg, Deutschland
| | - Thomas Bschleipfer
- Klinik für Urologie und Kinderurologie, Regiomed Klinikum, Coburg, Deutschland
| | | | - Klaus Höfner
- Klinik für Urologie, Evangelisches Krankenhaus, Oberhausen, Deutschland
| | | | - Giuseppe Magistro
- Klinik für Urologie, Asklepios Westklinikum GmbH, Hamburg, Deutschland
| | - Rolf Muschter
- Urologische Abteilung, ALTA Klinik, Bielefeld, Deutschland
| | - Matthias Oelke
- Klinik für Urologie, St. Antonius-Hospital GmbH, Gronau, Deutschland
| | | | | | - Sandra Schönburg
- Universitätsklinik und Poliklinik für Urologie und Nierentransplantation, Martin-Luther-Universität, Halle-Wittenberg, Deutschland
| | - Dominik Abt
- Klinik für Urologie, Spitalzentrum, Biel, Schweiz
| |
Collapse
|
|
13
|
Bilhim T, McWilliams JP, Bagla S. Updated American Urological Association Guidelines for the Management of Benign Prostatic Hyperplasia: Prostatic Artery Embolization Made it into the Guidelines! Cardiovasc Intervent Radiol 2024; 47:150-153. [PMID: 38010505 DOI: 10.1007/s00270-023-03617-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 11/05/2023] [Indexed: 11/29/2023]
Affiliation(s)
- Tiago Bilhim
- Interventional Radiology Unit, Centro Hospitalar Universitário de Lisboa Central (CHULC), SAMS Hospital, Lisbon, Portugal.
| | | | - Sandeep Bagla
- Prostate Centers USA, 2755 Hartland Rd #110, Falls Church, VA, 22043, USA
| |
Collapse
|
|
14
|
Movalled K, Zavvar M, Zafardoust H, Salehi-Pourmehr H, Arlandis S, Ghavidel-Sardsahra A, Hajebrahimi S. Level of Scientific Evidence Underlying Recommendations Arising from the Functional Urology Guidelines. UROLOGICAL SCIENCE 2023; 34:142-147. [DOI: 10.4103/uros.uros_82_22] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Accepted: 12/30/2022] [Indexed: 05/18/2025] Open
Abstract
Purpose:
This study aimed to review the functional urology guidelines, relate the level of evidence (LOE) of their recommendations and highlight the discrepancies between the LOE and grade of recommendation.
Materials and Methods:
The electronic search was conducted in May 2019 and updated in February 2021. Three researchers separately reviewed the extracted guidelines based on the Appraisal of Guidelines for Research and Evaluation II instrument. We extracted recommendations from each guideline and ranked them into three Grades of A, B, and C; and their evidence into four levels of I to IV.
Results:
Among the published functional urology guidelines, 18 guidelines were published between 2014 and 2020. Overall, 592 recommendations were abstracted. Of these, 121 recommendations were related to evaluation or diagnosis, and the others (n = 471) on the disease management. These recommendations were in the field of urinary incontinence (UI) (n = 216), overactive bladder (OAB) (n = 172), lower urinary tract symptoms (LUTS) (n = 126), and neurogenic bladder (NGB) (n = 78). Subgroup analysis showed that most of the recommendations in relation to UI were Grade A (n = 111; 51.4%), and one-third were Grade C (n = 83; 38.4%). The remaining 22 recommendations were Grade B (10.2%). In OAB, most of the recommendations were Grade B (n = 67, 39.0%), 55 of them were Grade A (32.0%) and the rest were Grade C (n = 50, 29.1%). Among UI guidelines, 51 (45.9%) Grade A recommendations were supported by LOE I evidence, and 39 (47.0%) Grade C recommendations were supported by LOE IV evidence. Across OAB guidelines, 43 (78.2%) Grade A recommendations were supported by LOE I evidence, and 20 (40.0%) Grade C recommendations were supported by LOE IV evidence. Across LUTS guidelines, 34 (61.8%) Grade A recommendations were supported by LOE I evidence, and 14 (23.3%) Grade C recommendations were supported by LOE IV evidence. Among NGB guidelines, 21 Grade A recommendations were supported by LOE I evidence, and 9 Grade C recommendations were supported by LOE IV evidence.
Conclusion:
Most of the recommendations in the field of functional urology are not based on the systematic review and meta-analysis of randomized controlled trials (RCTs) and high quality RCTs; which indicates that more attention is still needed in making decisions based on the certainty and grade of recommendations.
Collapse
Affiliation(s)
- Kobra Movalled
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
- Research Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Morteza Zavvar
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hooman Zafardoust
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hanieh Salehi-Pourmehr
- Research Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Salvador Arlandis
- Department of Urology, La Fe University and Polytechnic Hospital, Valencia, Spain
| | | | - Sakineh Hajebrahimi
- Research Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
- Urology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
|
15
|
Lehrer R, Sapoval M, Di Gaeta A, Querub C, Al Ahmar M, Dean C, Pellerin O, Boeken T. Benefits of Repeat Prostatic Artery Embolization on Persistent or Recurrent Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol 2023:10.1007/s00270-023-03424-y. [PMID: 37029235 DOI: 10.1007/s00270-023-03424-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Accepted: 03/16/2023] [Indexed: 04/09/2023]
Abstract
OBJECTIVES To evaluate the benefits of repeat prostatic artery embolization (rePAE) for patients with persistent or recurrent symptoms after initial prostatic artery embolization (PAE). MATERIALS AND METHODS This is a single-center retrospective study of all patients who underwent a rePAE between December 2014 and November 2020 for persistent or recurrent lower urinary tract symptoms. Symptoms were assessed before and after PAE and rePAE, using the International Prostate Symptom Score and quality of life (QoL) questionnaires. Patient characteristics, anatomical presentations, technical success rates, and complications of both procedures were collected. Clinical failure was defined as one of the following: less than 2 points' decrease in QoL, a QoL score higher than 3, acute urinary retention, and secondary surgery. RESULTS A total of 21 consecutive patients (mean age: 63.8 ± 8.1; [40-75] years) who underwent rePAE were included. The median follow-up after PAE was 27.7 [18.1-36.9]) months and 8.9 [3.4-10.8] months after rePAE. rePAE was performed at a mean of 19 ± 11.1 [6.9-49.6] months following PAE, and the overall clinical success rate was 33% (7/21). In patients undergoing rePAE because of persistent symptoms, the clinical success rate (18%) was non-significantly lower than that for patients treated for recurrent symptoms (50%) [OR 4.5 (95% CI 0.63-32 P = 0.13)]. The main anatomical revascularization pattern was recanalization of the native prostatic artery (29/45, 66%). CONCLUSION Patients who experience recurrent symptoms after PAE may benefit more from rePAE than those with persistent symptoms after PAE. Clinical success rates seem to be relatively low in both clinical scenarios.
Collapse
Affiliation(s)
- Raphael Lehrer
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Marc Sapoval
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
- Faculté de Santé, Université de Paris Cité, Paris, France
- PARCC U 970, INSERM, Université de Paris Cité, Paris, France
| | - Alessandro Di Gaeta
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Charles Querub
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
- Faculté de Santé, Université de Paris Cité, Paris, France
| | - Marc Al Ahmar
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Carole Dean
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
- PARCC U 970, INSERM, Université de Paris Cité, Paris, France
| | - Olivier Pellerin
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
- Faculté de Santé, Université de Paris Cité, Paris, France
- PARCC U 970, INSERM, Université de Paris Cité, Paris, France
| | - Tom Boeken
- Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
- Faculté de Santé, Université de Paris Cité, Paris, France.
- PARCC U 970, INSERM, Université de Paris Cité, Paris, France.
- HeKA Team, INRIA, Paris, France.
| |
Collapse
|
|
16
|
Chung E. Penile Glans Necrosis Following Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Case Series and Review of Current Literature. World J Mens Health 2023; 41:396-402. [PMID: 35791297 PMCID: PMC10042657 DOI: 10.5534/wjmh.210244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 02/26/2022] [Accepted: 03/05/2022] [Indexed: 11/15/2022] Open
Abstract
PURPOSE To report a case series of 6 patients with penile glans necrosis (PGN) following prostatic artery embolization (PAE) and review the current literature relating to PAE and PGN, including the emerging role of hyperbaric oxygen therapy (HBOT) for PGN. MATERIALS AND METHODS All patients have failed medical BPH therapy and chose to undergo PAE over other minimally invasive BPH surgery. Patient demographics, preoperative and postoperative validated questionnaires such as the International Prostate Symptom Severity (IPSS) and International Index of Erectile Function (IIEF) scores, treatment-related adverse events (TRAE) and subsequent treatment for PGN were reviewed. All patients were follow-up with a minimum of 12 months post-PAE. RESULTS Between January 2018 and June 2020, six males with a mean age of 52.3 years (44-66 y) received PAE for BPH therapy. An immediate postoperative PGN was recognised in 4 out of 6 patients with the mean penile glans pain score of 3 and 4 patients reported altered penile glans sensitivity. Comparing the mean (and median) IPSS and IIEF-5 scores were 16.5 (16) and 21.3 (21) pre-PAE, there was improvements in IPSS and IIEF-5 scores at 12.0 (12) and 18.0 (18) at 12 months review. All patients reported normal penile glans sensitivity and only 1 patient reported an on-going penile glans pain (score 2). Four patients received HBOT while 2 patients elected for conservative care. All patients reported worse erectile function scores despite complete resolution of PGN. CONCLUSIONS PGN is a rare but serious complication of PAE with ensuing erectile dysfunction. HBOT appears to expedite the recovery process in men with PGN related to PAE with better erection scores compared to conservative measure.
Collapse
Affiliation(s)
- Eric Chung
- AndroUrology Centre, Brisbane, QLD and Sydney, NSW, Australia
- Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Macquarie University Hospital, Sydney, NSW, Australia.
| |
Collapse
|
|
17
|
Alizadeh LS, Gyánó M, Góg I, Szigeti K, Osváth S, Kiss JP, Yel I, Koch V, Grünewald LD, Vogl TJ, Booz C. Initial Experience Using Digital Variance Angiography in Context of Prostatic Artery Embolization in Comparison with Digital Subtraction Angiography. Acad Radiol 2023; 30:689-697. [PMID: 35688786 DOI: 10.1016/j.acra.2022.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2022] [Revised: 05/11/2022] [Accepted: 05/11/2022] [Indexed: 11/23/2022]
Abstract
RATIONALE AND OBJECTIVES In previous clinical studies digital variance angiography (DVA) provided higher contrast-to-noise ratio (CNR) and better image quality in lower extremity angiography than digital subtraction angiography (DSA). Our aim was to investigate whether DVA has similar quality reserve in prostatic artery embolization (PAE). The secondary aim was to explore the potential advantages of the color-coded DVA (ccDVA) technology in PAE. MATERIAL AND METHODS This retrospective study evaluated 108 angiographic acquisitions from 30 patients (mean ± SD age 68.0 ± 8.9, range 41-87) undergoing PAE between May and October 2020. DSA and DVA images were generated from the same unsubtracted acquisition, and their CNR was calculated. Visual evaluation of DVA and DSA image quality was performed by four experienced interventional radiologists in a randomized, blinded manner. The diagnostic value of DSA and ccDVA images was also evaluated using clinically relevant criteria (visibility of small [< 2.5 mm] and large arteries [> 2.5 mm], feeding arteries and tissue blush) in a paired comparison. Data were analysed by the Wilcoxon signed rank test or the binomial test, the interrater agreement was determined by the Kendall W or Fleiss Kappa analysis. RESULTS DVA provided 4.11 times higher median CNR than DSA (IQR: 1.72). The visual score of DVA images (4.40 ± 0.05) was significantly higher than that of DSA (3.39 ± 0.07, p < 0.001). The Kendall W analysis showed moderate but significant agreement (WDVA = 0.38, WDSA = 0.53). The preference of ccDVA images was significantly higher in all criteria (63-89%) with an interrater agreement of 58-79%. The Fleiss Kappa range was 0.02-0.18, significant in all criteria except large vessels. CONCLUSION Our data show that DVA provides higher CNR and better image quality in PAE. This quality reserve might be used for dose management (reduction of radiation dose and contrast agent volume), and ccDVA technology has also a high potential to assist PAE interventions in the future.
Collapse
Affiliation(s)
- Leona S Alizadeh
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany.
| | - Marcell Gyánó
- The Heart and Vascular Center, Semmelweis University, Budapest, Hungary; Research Department, Kinepict Health Ltd, Budapest, Hungary
| | - István Góg
- The Heart and Vascular Center, Semmelweis University, Budapest, Hungary; Research Department, Kinepict Health Ltd, Budapest, Hungary; The Department of Vascular Surgery, Hungarian Defence Forces Medical Centre, Budapest, Hungary
| | - Krisztián Szigeti
- Research Department, Kinepict Health Ltd, Budapest, Hungary; The Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - Szabolcs Osváth
- Research Department, Kinepict Health Ltd, Budapest, Hungary; The Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
| | - János P Kiss
- Research Department, Kinepict Health Ltd, Budapest, Hungary
| | - Ibrahim Yel
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany
| | - Vitali Koch
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany
| | - Leon D Grünewald
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany
| | - Thomas J Vogl
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany
| | - Christian Booz
- The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany
| |
Collapse
|
|
18
|
Zoppo CT, Taros T, Harman A. Top 50 most cited articles on prostatic artery embolization for benign prostatic hyperplasia: A bibliometric review. World J Clin Urol 2023; 12:1-9. [DOI: 10.5410/wjcu.v12.i1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 12/17/2022] [Accepted: 02/22/2023] [Indexed: 03/08/2023] Open
Abstract
BACKGROUND Bibliometric analysis can be used to assess the current state of the literature and publication trends on a given topic. There has not been a review of this kind on prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH). PAE is a relatively new and somewhat controversial treatment option for BPH. Given the novelty and controversy, there has been much research published on the topic recently.
AIM To survey the current state of research on PAE for BPH by using bibliometric analysis to analyze the top 50 most highly cited articles.
METHODS A cross-sectional study was performed using the Web of Science database to identify the most cited articles published on PAE for BPH as of June 2022. Articles that did not primarily focus on PAE or BPH as an indication were eliminated. The 50 most cited articles were carried forward for analysis.
RESULTS All but 6 articles were published in the last decade with contributions from 15 countries. Fifty-two percent of the studies had a C level of evidence. The majority were published in the Journal of Vascular and Interventional Radiology and Cardiovascular and Interventional Radiology. Twenty percent (n = 10) of the articles were published in urologic journals. On average, articles published in urologic journals tended to be more recent. The mean year of publication for an article in a urological journal was 2016.6 compared to 2013.9 in a non-urologic journal (P = 0.02). Seventy percent of the articles focused on clinical outcomes, while only 2% focused on practice guidelines. Self-citations accounted for 11.4 citations per article on average, corresponding to 14.7% of all citations analyzed.
CONCLUSION The most influential papers on this topic represent a fairly recent body of work with contributions from a wide variety of countries and journals. The fact that articles in urologic journals were published significantly more recently than articles on the list in non-urologic journals may suggest that the field of urology is starting to accept PAE for a wider range of indications. Finally, while there has been much high-quality research published, more influential studies on practice guidelines and technique may be beneficial.
Collapse
Affiliation(s)
- Christopher Thomas Zoppo
- Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA 01604, United States
| | - Trenton Taros
- Department of Radiology, University of Massachusetts Chan Medical School, Worcester, MA 01604, United States
| | - Aaron Harman
- Interventional Radiology, Prostate Laser Center, Houston, TX 77030, United States
| |
Collapse
|
|
19
|
Boschheidgen M, Al-Monajjed R, Minko P, Jannusch K, Ullrich T, Radke KL, Michalski R, Radtke JP, Albers P, Antoch G, Schimmöller L. Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization. CVIR Endovasc 2023; 6:9. [PMID: 36859572 PMCID: PMC9978045 DOI: 10.1186/s42155-023-00357-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 02/14/2023] [Indexed: 03/03/2023] Open
Abstract
BACKGROUND To investigate the influence of benign prostatic hyperplasia (BPH) patterns detected with MRI on clinical outcomes after prostatic artery embolization (PAE). MATERIALS & METHODS This retrospective study included 71 consecutive patients with lower urinary tract symptoms (LUTS), who underwent magnetic resonance imaging (MRI) of the prostate followed by PAE at a single centre. MRI scans were evaluated and BPH patterns were determined according to Wasserman type and a modified BPH classification. Additionally, scans were evaluated regarding the presence of adenomatous-dominant benign prostatic hyperplasia (AdBPH). LUTS were assessed using the International Prostate Symptom Score (IPSS) and urinary flow rate (Qmax). Follow-up examination included MRI and clinical outcome. RESULTS For clinical outcome at follow-up, IPSS showed median reduction of 54% (IQR 41-75%) and Qmax improved by 4.1 ml/s. We noted significant reduction in volume, intraprostatic protrusion, and prostatic urethral angle in our collective (p < 0.01). Median volume reduction was 25% (IQR 15%-34%). Bilateral embolization was a significant predictor for volume reduction at follow-up. Multiple linear regression analysis showed significant effect of high initial volume on reduction in IPSS after treatment (p < 0.01). Presence of AdBPH was significantly associated with both, volume loss and clinical improvement in terms of IPSS reduction (p < 0.01). Neither BPH pattern based on the Wassermann type nor modified BPH classification were significantly related with postinterventional IPSS and volume loss. CONCLUSIONS Men benefit from PAE regardless the macroscopic BPH MRI pattern. Preinterventional prostate volume and presence of AdBPH on MRI should be considered for outcome prognosis after PAE.
Collapse
Affiliation(s)
- Matthias Boschheidgen
- Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225, Germany.
| | - Rouvier Al-Monajjed
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Peter Minko
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Kai Jannusch
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Tim Ullrich
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Karl Ludger Radke
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Rene Michalski
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Jan Philipp Radtke
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Peter Albers
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Gerald Antoch
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| | - Lars Schimmöller
- grid.411327.20000 0001 2176 9917Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, Dusseldorf, D-40225 Germany
| |
Collapse
|
|
20
|
Long-term outcomes of prostate artery embolization for acute urinary retention: An analysis of 88 patients. Diagn Interv Imaging 2023; 104:292-296. [PMID: 36801097 DOI: 10.1016/j.diii.2023.01.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 01/27/2023] [Accepted: 01/31/2023] [Indexed: 02/18/2023]
Abstract
PURPOSE The purpose of this study was to assess long-term outcome of prostate artery embolization (PAE) in patients presenting with acute urinary retention related to benign prostatic hyperplasia. MATERIALS AND METHODS All consecutive patients who underwent PAE for acute urinary retention due to benign prostatic hyperplasia from August 2011 to December 2021 in a single institution were retrospectively included. There were 88 men with a mean age of 72 ± 12 (standard deviation [SD]) years (range: 42-99 years). Patients underwent a first attempt of catheter removal two weeks after PAE. Clinical success was defined as the absence of acute urinary retention recurrence. Correlations between long-term clinical success and patient variables or bilateral PAE were searched for using Spearman correlation test. Catheter-free survival was assessed using Kaplan-Meier analysis. RESULTS Successful catheter removal in the month following PAE was performed in 72 (72/88; 82%) patients and 16 (16/88; 18%) patients had immediate recurrence. Clinical success persisted for 58 (58/88; 66%) patients at long-term follow-up (mean follow-up: 19.5 months ± 16.5 [SD]; range: 2-74 months). Recurrence occurred at a mean of 16.2 months ± 12.2 (SD) (range: 1.5-43 months) post-PAE. Overall, 21 (21/88; 24%) patients of the cohort underwent prostatic surgery, at a mean of 10.4 months ± 12.2 (SD) (range: 1.2-42.4 months) from initial PAE. No correlations between patients variables or bilateral PAE and long-term clinical success were identified. Kaplan-Meier analysis showed a three-year catheter free probability of 60%. CONCLUSION PAE is a valuable technique for acute urinary retention related to benign prostatic hyperplasia, with a long-term success rate of 66%. However acute urinary retention relapse affects 15% of patients.
Collapse
|
|
21
|
Powell T, Rahman S, Staib L, Bhatia S, Ayyagari R. Operator Learning Curve for Prostatic Artery Embolization and Its Impact on Outcomes in 296 Patients. Cardiovasc Intervent Radiol 2023; 46:229-237. [PMID: 36456689 DOI: 10.1007/s00270-022-03321-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 11/16/2022] [Indexed: 12/02/2022]
Abstract
PURPOSE To define operator learning curve inflection points for prostatic artery embolization (PAE) and their impact on technical efficiency, clinical outcomes, and adverse events. MATERIALS AND METHODS Between May 2013 and May 2021, 296 consecutive patients with moderate-to-severe lower urinary tract symptoms, urinary retention, or gross hematuria from benign prostatic hyperplasia underwent PAE by an interventional radiologist without prior PAE-specific experience. Operator learning curves plotted procedure time, fluoroscopy time, contrast volume, and embolic endpoint data against sequential procedure number. Multiple regression analysis evaluated for improvements in these parameters, with segmented linear regression to detect learning curve inflection points. Linear and logistic regression evaluated for learning curve impacts on 6-month clinical outcomes and 90-day adverse events. RESULTS No baseline patient characteristic varied over the series apart from decreasing pre-procedural gland volume (P < 0.01). Multiple regression analysis demonstrated experience-dependent improvements in procedure time, fluoroscopy time, and contrast volume (P < 0.01), with corresponding learning curve inflection points at 76 (P < 0.01), 78 (P < 0.01), and 73 (P = 0.10) procedures. Embolic endpoints did not vary with experience (P > 0.05). Post-procedure reductions in International Prostate Symptom Score (21.5 ± 6.2 to 6.7 ± 4.7), Quality of Life score (4.5 ± 1.2 to 1.3 ± 1.2), post-void residual (190 ± 203 to 97 ± 148 mL), and gland volume (142 ± 97 to 76 ± 47 mL) were substantial (P < 0.01) but did not vary with experience (P > 0.05), nor did adverse event frequency/severity (P > 0.05). CONCLUSION Operator technical efficiency plateaued after 73-78 PAE procedures. Clinical improvements were substantial and adverse event frequency/severity low, and neither varied with experience. Operators without prior PAE-specific experience may perform PAE safely and effectively from the outset. LEVEL OF EVIDENCE Level 2b, Cohort Study.
Collapse
Affiliation(s)
- Taylor Powell
- Yale University School of Medicine, New Haven, CT, USA
| | - Saumik Rahman
- Yale University School of Medicine, New Haven, CT, USA
| | | | | | | |
Collapse
|
|
22
|
Jung JH, McCutcheon KA, Borofsky M, Young S, Golzarian J, Kim MH, Narayan V, Dahm P. Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review. BJU Int 2023; 131:32-45. [PMID: 35696302 DOI: 10.1111/bju.15823] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVES To assess the effects of prostatic arterial embolisation (PAE) compared to other procedures for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). METHODS We included randomised controlled trials (RCTs), as well as non-randomised studies (NRSs) enrolling men with BPH undergoing PAE vs other surgical interventions via a comprehensive search up until 8 November 2021. Two independent reviewers screened the literature, extracted data, assessed risk of bias, performed statistical analyses by using a random-effects model, and rated the certainty of evidence (CoE) of RCTs and NRSs. RESULTS We found data to inform two comparisons: PAE vs transurethral resection of prostate (TURP; six RCTs and two NRSs), and PAE vs sham (one RCT). This abstract focuses on the primary outcomes in a comparison of PAE vs TURP. Short-term follow-up: based on RCT evidence, there may be little to no difference in urological symptom score improvement (mean difference [MD] 1.72, 95% confidence interval [CI] -0.37 to 3.81; low CoE) and quality of life (QoL; MD 0.28, 95% CI -0.28 to 0.84; low CoE) measured by International Prostatic Symptom Score. We are very uncertain about the effects of PAE on major adverse events (risk ratio [RR] 0.75, 95% CI 0.19-2.97; very low CoE). Long-term follow-up: based on RCT evidence, PAE may result in little to no difference in urological symptom scores (MD 2.58, 95% CI -1.54 to 6.71; low CoE) and QoL (MD 0.50, 95% CI -0.03 to 1.04; low CoE). We are very uncertain about major adverse events (RR 0.91, 95% CI 0.20-4.05; very low CoE). CONCLUSION Compared to TURP, the impact on urological symptoms and QoL improvement as perceived by patients appears to be similar. This review did reveal major uncertainty as to how major adverse events compare.
Collapse
Affiliation(s)
- Jae Hung Jung
- Department of Urology, Yonsei University Wonju College of Medicine, Wonju, South Korea.,Center of Evidence Based Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea
| | | | - Michael Borofsky
- Department of Urology, University of Minnesota, Minneapolis, MN, USA
| | - Shamar Young
- Division of Interventional Radiology and Vascular Imaging, Department of Radiology, University of Minnesota, Minneapolis, MN, USA
| | - Jafar Golzarian
- Division of Interventional Radiology and Vascular Imaging, Department of Radiology, University of Minnesota, Minneapolis, MN, USA
| | - Myung Ha Kim
- Yonsei Wonju Medical Library, Yonsei University Wonju College of Medicine, Wonju, South Korea
| | - Vikram Narayan
- Department of Urology, University of Minnesota, Minneapolis, MN, USA
| | - Philipp Dahm
- Department of Urology, University of Minnesota, Minneapolis, MN, USA.,Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA
| |
Collapse
|
|
23
|
Raizenne BL, Zheng X, Oumedjbeur K, Mao J, Zorn KC, Elterman D, Bhojani N, McClure T, Te A, Kaplan S, Sedrakyan A, Chughtai B. Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study. World J Urol 2023; 41:179-188. [PMID: 36463348 DOI: 10.1007/s00345-022-04218-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 11/04/2022] [Indexed: 12/07/2022] Open
Abstract
BACKGROUND There are growing interests for minimally invasive surgical techniques (MISTs) for the treatment of benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). Prostatic artery embolization (PAE) uses selective angioembolization of prostatic arteries, thereby reducing size to improve LUTS/BPH. However, real-world data comparing surgical outcomes between MISTs and tissue resective techniques are lacking. We assessed the differences in surgical outcomes between PAE, transurethral resection of the prostate (TURP), and prostatic urethral lift (PUL) in a real-world population for LUTS/BPH. METHODS We present an observational population-based study of 12,902 men with BPH in New York State who received PAE, TURP, and PUL in outpatient and ambulatory surgery settings from 2014 to 2018. For short-term outcomes, we report 30-day and 90-day risks of readmission to inpatient and emergency room (ER) with/without complications and compared them across groups using χ2 tests and mixed-effect logistic regressions. For long-term outcomes, we report surgical retreatment and stricture rates using Kaplan-Meier failure curves and compared them using Log rank tests and Cox regression models. RESULTS Of 12 902 men, 335 had PAE, 11,205 had TURP, and 1362 had PUL. PAE patients had the highest 30-day (19.9%) and 90-day (35.6%) risks of readmission to inpatient or ER (p < 0.01). Non-specific abdominal pain was the main diagnosis associated with 30-day and 90-day readmissions to inpatient or ER after PAE (14.3% and 26.8%, respectively). After 2 years of follow-up, PAE patients had the highest retreatment rate of 28.5% (95%CI 23.7-34.2%) compared to TURP (3.4% (95%CI 3.1-3.8%)) and PUL (8.5% (95%CI 5.6-12.9%)) (p < 0.001). CONCLUSION In a real-world population, PAE was associated with the most frequent 30-day and 90-day readmission to inpatient or ER and the highest retreatment rate among all surgical techniques even when controlled for individual patient comorbidities and surgical volume.
Collapse
Affiliation(s)
- Brendan L Raizenne
- Division of Urology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Xinyan Zheng
- Department of Population Health Sciences, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA
| | | | - Jialin Mao
- Department of Population Health Sciences, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA
| | - Kevin C Zorn
- Division of Urology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Dean Elterman
- Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada
| | - Naeem Bhojani
- Division of Urology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Timothy McClure
- Department of Urology, Weill Cornell Medical College/New York Presbyterian, 425 East 61St St., 12th Floor, New York, NY, 10065, USA
| | - Alexis Te
- Department of Urology, Weill Cornell Medical College/New York Presbyterian, 425 East 61St St., 12th Floor, New York, NY, 10065, USA
| | - Steven Kaplan
- Department of Urology, Mount Sinai Hospital, New York, NY, USA
| | - Art Sedrakyan
- Department of Population Health Sciences, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA
| | - Bilal Chughtai
- Department of Population Health Sciences, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA. .,Department of Urology, Weill Cornell Medical College/New York Presbyterian, 425 East 61St St., 12th Floor, New York, NY, 10065, USA.
| |
Collapse
|
|
24
|
Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G, Carrafiello G. Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). Technol Cancer Res Treat 2023; 22:15330338231155000. [PMID: 36794408 PMCID: PMC9936536 DOI: 10.1177/15330338231155000] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Review efficacy and safety of minimally-invasive treatments for Low Urinary Tract Symptoms (LUTS) in patients affected by Benign Prostate Hyperplasia (BPH). We performed a systematic review of the literature from 1993 to 2022 leveraging original research articles, reviews, and case-studies published in peer-reviewed journals and stored in public repositories. Prostate artery embolization (PAE), transurethral needle ablation (TUNA), transurethral microwave thermotherapy (TUMT), high intensity focused ultrasound (HIFU), laser treatments and Cryoablation are valid and safe alternatives to the gold standard (surgery) in the treatment of LUTS in patients affected by BPH, with fewer undesired effects being reported.
Collapse
Affiliation(s)
- L V Sciacqua
- Residency Program in Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy
| | - A Vanzulli
- Residency Program in Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy
| | - R Di Meo
- Residency Program in Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy
| | - G Pellegrino
- Residency Program in Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy
| | - R Lavorato
- Researcher at Diagnostic and Interventional Radiology Department, IRCCS Ca' Granda Fondazione Ospedale Maggiore Policlinico, Milan, Italy
| | - G Vitale
- Department of Medical Biotechnology and Translational Medicine, 9304University of Milan, Milan, Italy.,Istituto Auxologico Italiano, IRCCS, Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Milan, Italy
| | - G Carrafiello
- Diagnostic and Interventional Radiology Department, IRCCS Ca' Granda Fondazione Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
|
25
|
de Assis AM, Kawakami WY, Moreira AM, Carnevale FC. Prostatic artery embolization using reflux-control microcatheter: prospective experience addressing feasibility. CVIR Endovasc 2022; 5:62. [PMID: 36477441 PMCID: PMC9729574 DOI: 10.1186/s42155-022-00337-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 11/08/2022] [Indexed: 12/12/2022] Open
Abstract
PURPOSE To evaluate the efficacy and safety of Prostatic Artery Embolization (PAE) using a reflux control microcatheter. MATERIALS AND METHODS This is a prospective, single-center investigation that included 10 patients undergoing PAE for treatment of lower urinary tract symptoms (LUTS) attributed to benign prostate hyperplasia (BPH). Baseline, 3-month, and 12-month efficacy endpoints were obtained for all patients and included prostate-specific antigen (PSA), uroflowmetry, pelvic magnetic resonance imaging (MRI), and clinical assessment using the International Prostate Symptom Score (IPSS) questionnaire and the IPSS-Quality of life (QoL) item. Complications were assessed using the Cirse classification system. RESULTS Ten patients entered statistical analysis and presented with significant LUTS improvement 12 months after PAE, as follows: mean IPSS reduction of 86.6% (2.8 vs. 20.7, - 17.9, P < 0.001), mean QoL reduction of 79.4% (1.1 vs. 5.4, - 4.3, P < 0.001), mean prostatic volume reduction of 38.4% (69.3 cm3 vs. 112.5 cm3, - 43.2 cm3, P < 0.001), mean peak urinary flow (Qmax) increase of 199.4% (19.9 mL/s vs. 6.6 mL/s, + 13.3 mL/s, P = 0.006) and mean PSA reduction of 50.1% (3.0 ng/mL vs. 6.1 ng/mL, - 3.0 ng/mL, P < 0.001). One patient (10%) needed transurethral resection of the prostate (TURP) after PAE due to a ball-valve effect. One microcatheter (10%) needed to be replaced during PAE due to occlusion. Non-target embolization was not observed in the cohort. CONCLUSION This initial experience suggests that PAE using a reflux control microcatheter is effective and safe for the treatment of LUTS attributed to BPH.
Collapse
Affiliation(s)
- André Moreira de Assis
- grid.11899.380000 0004 1937 0722Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, São Paulo, 05403-000 Brazil
| | - Willian Yoshinori Kawakami
- grid.11899.380000 0004 1937 0722Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, São Paulo, 05403-000 Brazil
| | - Airton Mota Moreira
- grid.11899.380000 0004 1937 0722Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, São Paulo, 05403-000 Brazil
| | - Francisco Cesar Carnevale
- grid.11899.380000 0004 1937 0722Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, São Paulo, 05403-000 Brazil
| |
Collapse
|
|
26
|
Veyg D, Mohanka R, Rumball IP, Liang R, Garcia-Reyes K, Bishay V, Fischman AM. Comparison of 24-Month Clinical Outcomes after Prostatic Artery Embolization in Prostate Glands Larger versus Smaller than 80 mL: A Systematic Review. J Vasc Interv Radiol 2022; 34:578-584.e1. [PMID: 36470516 DOI: 10.1016/j.jvir.2022.11.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 11/05/2022] [Accepted: 11/24/2022] [Indexed: 12/12/2022] Open
Abstract
PURPOSE This review was undertaken to compare the clinical outcomes of prostatic artery embolization (PAE) in patients with >80 versus <80 mL prostatic volume (PV) at the 24-month follow-up to determine whether PV predicted the effectiveness or durability of PAE. MATERIALS AND METHODS The PubMed/MEDLINE database was searched for articles published between 2010 and 2022 using the search term "(prostat∗ artery embolization) AND (long term OR follow-up OR 24-month)." Articles were included if they discussed PAE for benign prostatic hyperplasia (BPH) and reported a minimum follow-up of 24 months. Articles with <10 patients were excluded. A subgroup analysis was performed to evaluate for any difference in clinical outcomes at the 24-month post-PAE follow-up between studies with a mean PV of >80 mL and those with a mean PV of <80 mL. RESULTS A total of 14 studies with 2,260 patients were included, all of which demonstrated significant reduction in symptoms at the 24-month follow-up after PAE. Four studies were included as part of the >80-mL PV subgroup (n = 467), and 10 studies were included as part of the <80-mL PV subgroup (n = 1,793). There was a statistically significant difference between the mean preprocedural PV (128.5 vs 64.0 mL; P = .015). At the 24-month follow-up, there were no significant differences between groups across any of the compared parameters. The collective incidence of major adverse events reported in the studies within this review was <1%. CONCLUSIONS PAE is both safe and durable for patients suffering from BPH and can be effective across a wide range of baseline PVs.
Collapse
Affiliation(s)
- Daniel Veyg
- Long Island Jewish Medical Center, Northwell Health System, Queens, New York.
| | - Rajat Mohanka
- New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York
| | - Ian P Rumball
- Zucker School of Medicine at Hofstra University/Northwell Health System, Hempstead, New York
| | - Richard Liang
- New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York
| | | | - Vivian Bishay
- Icahn School of Medicine at Mount Sinai Hospital, New York, New York
| | - Aaron M Fischman
- Icahn School of Medicine at Mount Sinai Hospital, New York, New York
| |
Collapse
|
|
27
|
Abstract
Benign prostatic hyperplasia (BPH) is a condition that primarily affects men between the fourth and seventh decades of life, occurring due to enlargement of the prostate which subsequently causes compression of the prostatic urethra causing chronic obstruction of the urinary outflow tract. BPH can cause significant quality-of-life issues such as urinary hesitancy, intermittency, decreased urinary stream, a sensation of incomplete emptying, dysuria, urinary retention, hematuria, and nocturia. Several medical and surgical treatment modalities are available for the treatment of lower urinary tract symptoms and other BPH-related sequela; however, increasingly prostate artery embolization is being utilized in this patient population. Technical demands for this procedure in this population can be significant. This article describes the optimal techniques, tricks, and advanced imaging techniques that can be used to achieve desired technical outcomes.
Collapse
Affiliation(s)
- Ansh Bhatia
- Seth G.S. Medical College and King Edward Memorial Hospital, Mumbai, India
| | - Aneesha Maini
- M2 at Georgetown University School of Medicine, Washington, District of Columbia
| | - Shivank Bhatia
- Department of Interventional Radiology, University of Miami, Miami, Florida
| |
Collapse
|
|
28
|
Lucas-Cava V, Sánchez-Margallo FM, Dávila-Gómez L, Lima-Rodríguez JR, Sun F. Prostatic artery occlusion versus prostatic artery embolisation for the management of benign prostatic hyperplasia: early results in a canine model. Br J Radiol 2022; 95:20220243. [PMID: 35762334 PMCID: PMC10162044 DOI: 10.1259/bjr.20220243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 05/02/2022] [Accepted: 05/24/2022] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE To compare the technical efficacy and safety between prostatic artery occlusion (PAO) with ethylene vinyl alcohol copolymer (EVOH) and prostatic artery embolizsation (PAE) with microspheres in a canine model. METHODS 17 adult male beagles underwent PAO (n = 7) with Onyx-18 or PAE (n = 10) with microspheres (300-500 µm). To evaluate the primary outcomes (technical efficacy and safety), MRI evaluations were performed immediately before and 1 week, 2 weeks, and 1 month after procedures to document prostate volume (PV); and all dogs were inspected for procedure-related complications during 1 month follow-up. The secondary outcomes included the prostate ischaemia size detected by MRI and recanalisation of prostatic artery by follow-up angiography. Differences between groups were statistically analysed. RESULTS Both procedures were bilaterally successful in all animals. Compared with PAE, the mean fluoroscopy time (23.80 vs 36.24 min, p = 0.014) and radiation dose (68.19 vs 125.26 mGy, p = 0.003) were significantly less in PAO procedure. The mean percentage of PV change significantly decreased in both groups at 2 weeks (30.71% vs 37.89%) and 1 month (56.41% %vs 55.56%) after PAO and PAE respectively), without significant differences between groups at either time point. No major complications were observed except one animal after PAO with transient haematuria and acute urinary retention. The mean prostate ischaemia induced by PAO was significant greater compared with PAE at 1 week (43.44% vs 18.91%, p=0.001). PAO with EVOH is technically feasible and with comparable efficacy and safety with PAE. There are possible benefits to PAO over PAE. ADVANCES IN KNOWLEDGE A new technical modification of the PAE consisting of the use of liquid embolic agent to occlude the prostatic artery trunk and its branches has been developed in pre-clinical study, showing to be an effective and safe procedure which can induce a significant prostate shrinkage for the management of symptomatic benign prostatic hyperplasia in patients. In addition, the findings have showed a similar therapeutic effect comparable with the conventional PAE using microspheres.
Collapse
Affiliation(s)
- Vanesa Lucas-Cava
- Endoluminal Therapy and Diagnosis Unit, Jesús Usón Minimally Invasive Surgery Centre, Cáceres, Spain
| | | | - Luis Dávila-Gómez
- Animal Housing Service, Jesús Usón Minimally Invasive Surgery Centre, Cáceres, Spain
| | | | | |
Collapse
|
|
29
|
Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-Term Outcome of Prostatic Artery Embolization for Patients with Benign Prostatic Hyperplasia: Single-Centre Retrospective Study in 1072 Patients Over a 10-Year Period. Cardiovasc Intervent Radiol 2022; 45:1324-1336. [PMID: 35778579 DOI: 10.1007/s00270-022-03199-8] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 06/04/2022] [Indexed: 11/02/2022]
Abstract
PURPOSE Assess long-term outcomes of prostatic artery embolization (PAE) for patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS Single centre retrospective study from 2009-2019 including 1072 patients who received PAE and had available follow-up. Patients were evaluated yearly at 1-10 years post PAE using the International Prostate Symptom Score (IPSS) and quality of life (QoL), prostate volume (PV), prostate-specific antigen (PSA), peak urinary flow rate (Qmax) and postvoid residual (PVR) volume. The need for prostatic medication, re-intervention rates, repeat PAE and prostatectomy rates were assessed with Kaplan-Meier survival analysis and compared between different embolic agents using Cox regression analysis. RESULTS Mean follow-up time was 4.39 ± 2.37 years. At last follow-up visit, mean IPSS and QoL improvements were - 10.14 ± 8.34 (p < .0001) and - 1.87 ± 1.48 (p < .0001) points, mean PV reduction was - 6.82 ± 41.11 cm3 (p = 0.7779), mean PSA reduction was - 1.12 ± 4.60 ng/mL (p = 0.9713), mean Qmax increase was 2.72 ± 6.38 mL/s (p = 0.0005), mean PVR reduction was - 8.35 ± 135.75 mL (p = 0.6786). There were 335 patients (31.3%) needing prostatic medication after PAE. Re-intervention rates were 3.4% at 1 year, 21.1% at 5 years and 58.1% at 10 years. Repeat-PAE rates were 2.3% at 1 year, 9.5% at 5 years and 23.1% at 10 years. Prostatectomy rates were 1.1% at 1 year, 11.6% at 5 years and 35.0% at 10 years. No significant differences were found between polyvinyl alcohol particles, Bead Block, Embospheres and Embozenes. CONCLUSION PAE induces durable long-term LUTS relief, with re-intervention rates of 20% in the first 5 years and 30%-60% > 5 years post-PAE.
Collapse
Affiliation(s)
- Tiago Bilhim
- Interventional Radiologist, Interventional Radiology Unit, Saint Louis Hospital, R. Luz Soriano 182, 1200-249, Lisbon, Portugal. .,NOVA Medical School
- Faculdade de Ciências Médicas, NMS
- FCM, Universidade Nova de Lisboa, Lisbon, Portugal. .,Urology Department, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal.
| | - Nuno Vasco Costa
- Interventional Radiologist, Interventional Radiology Unit, Saint Louis Hospital, R. Luz Soriano 182, 1200-249, Lisbon, Portugal.,NOVA Medical School
- Faculdade de Ciências Médicas, NMS
- FCM, Universidade Nova de Lisboa, Lisbon, Portugal.,Urology Department, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| | - Daniel Torres
- Interventional Radiologist, Interventional Radiology Unit, Saint Louis Hospital, R. Luz Soriano 182, 1200-249, Lisbon, Portugal.,NOVA Medical School
- Faculdade de Ciências Médicas, NMS
- FCM, Universidade Nova de Lisboa, Lisbon, Portugal.,Urology Department, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| | - Luís Campos Pinheiro
- NOVA Medical School
- Faculdade de Ciências Médicas, NMS
- FCM, Universidade Nova de Lisboa, Lisbon, Portugal.,Urology Department, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| | | |
Collapse
|
|
30
|
Talaie R, Torkian P, Amili O, Aboufirass Y, Rostambeigi N, Jalaeian H, Golzarian J. Particle Distribution in Embolotherapy, How Do They Get There? A Critical Review of the Factors Affecting Arterial Distribution of Embolic Particles. Ann Biomed Eng 2022; 50:885-897. [PMID: 35524027 DOI: 10.1007/s10439-022-02965-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 04/05/2022] [Indexed: 11/26/2022]
Abstract
Embolization has tremendously evolved in recent years and has expanded to treatment of a variety of pathologic processes. There has been emerging evidence that the level of arterial occlusion and the distribution of embolic particles may play an important role in the clinical outcome. This is a comprehensive literature review to identify variables that play important role in determination of level of occlusion of blood vessels and distribution of embolic particles. The literature searches between 1996 to 2020 through PubMed and Ovid-MEDLINE yielded over 1030 articles of which 30 studies providing details on the level of occlusion are reviewed here. We divided the playing factors into characteristics of the particles, solution/injection and vascular bed. Accordingly, particle size, type and aggregation, compressibility/deformability, and biodegradability are categorized as the factors involving particles' behavioral nature. Infusion rate and concentration/dilution of the medium are related to the carrying solution. Hemodynamics and the arterial resistance are characteristics of the vascular bed that also play an important role in the distribution of embolic particles. Understanding and predicting the level of embolization is a complex multi-factor problem that requires more evidence, warranting further randomized controlled trials, and powered human and animal studies.
Collapse
Affiliation(s)
- Reza Talaie
- Department of Vascular and Interventional Radiology, University of Minnesota, Minneapolis, MN, USA
| | - Pooya Torkian
- Department of Vascular and Interventional Radiology, University of Minnesota, Minneapolis, MN, USA.
| | - Omid Amili
- Department of Mechanical, Industrial and Manufacturing Engineering (MIME), University of Toledo, Toledo, OH, USA
| | | | - Nassir Rostambeigi
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
| | - Hamed Jalaeian
- Department of Interventional Radiology, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - Jafar Golzarian
- Department of Vascular and Interventional Radiology, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
|
31
|
Bhatia S, Acharya V, Jalaeian H, Kumar J, Bryant E, Richardson A, Malkova K, Harward S, Sinha V, Kably I, Kava BR. Effect of Prostate Artery Embolization on Erectile Function - A Single Center Experience of 167 Patients. J Sex Med 2022; 19:594-602. [PMID: 35184995 DOI: 10.1016/j.jsxm.2022.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 01/03/2022] [Accepted: 01/10/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Prostate artery embolization (PAE) is an emerging therapy for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). AIM This retrospective study was conducted to assess the effect of prostate artery embolization (PAE) on erectile function in a cohort of patients with LUTS attributable to BPH at 3-months after the procedure. METHODS A retrospective review was performed on 167 patients who underwent PAE. Data collected included Sexual Health Inventory in Men (SHIM) scores at 3, 6, and 12 months post-PAE, in conjunction with the International Prostate Symptom Scores (IPSS), Quality of Life (QoL) scores, and prostate volumes. Primary outcome was erectile function as assessed by SHIM scores at 3 months after PAE. An analysis was performed to identify patients with a ±5-point SHIM change to group them according to this minimum clinically significant difference in erectile function. Adverse events were recorded using the Clavien-Dindo (CD) classification. OUTCOMES At 3 months following PAE, median IPSS decreased by 16.0 [IQR, 9.0-22.0] points, median QOL decreased by 4.0 [IQR, 2.0-5.0] points, and median prostate volume decreased by 33 g [IQR, 14-55]. RESULTS Median SHIM score was 17.0 [IQR, 12.0-22.0] at baseline, 18.0 [IQR, 14.0-23.0] at 3 months [P = .031], 19.0 [IQR, 14.5-21.5] at 6 months [P = .106] and 20 [IQR, 16.0-24.0] at 12 months [P = .010] following PAE. In patients with no erectile dysfunction (ED) at baseline, 21% (n = 9) reported some degree of decline in erectile function post-PAE. However, 38% (n = 40) of patients who presented with mild-to-moderate ED reported improvement in their erectile function 3 months following PAE. Overall, the changes in baseline SHIM score were relatively small; 82% (n = 137) of patients did not have more than 5 points of change in their SHIM scores at 3 months following PAE. CLINICAL IMPLICATIONS Our findings suggest PAE has no adverse impact on erectile function for most patients. STRENGTHS & LIMITATIONS The study was performed at a single center with 1 operator's experience, and is retrospective with no control group. CONCLUSION Findings suggest that prostate artery embolization has no adverse effect on erectile function in the majority of patients with LUTS attributable to BPH at 3 months after the procedure. Bhatia S, Acharya V, Jalaeian H, et al., Effect of Prostate Artery Embolization on Erectile Function - A Single Center Experience of 167 Patients. J Sex Med 2022;19:594-602.
Collapse
Affiliation(s)
- Shivank Bhatia
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Vedant Acharya
- University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Hamed Jalaeian
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Jessica Kumar
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA.
| | - Evan Bryant
- University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Andrew Richardson
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Kseniia Malkova
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Sardis Harward
- University of Massachusetts Medical School, Worcester, MA, USA
| | - Vishal Sinha
- Weill Cornell Department of Radiology, New York, NY, USA
| | - Issam Kably
- Department of Interventional Radiology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Bruce R Kava
- Department of Urology, University of Miami, Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
|
32
|
Jung JH, McCutcheon KA, Borofsky M, Young S, Golzarian J, Kim MH, Narayan VM, Dahm P. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2022; 3:CD012867. [PMID: 35349161 PMCID: PMC8962961 DOI: 10.1002/14651858.cd012867.pub3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND A variety of minimally invasive surgical approaches are available as an alternative to transurethral resection of the prostate (TURP) for management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Prostatic arterial embolization (PAE) is a relatively new, minimally invasive treatment approach. OBJECTIVES To assess the effects of PAE compared to other procedures for treatment of LUTS in men with BPH. SEARCH METHODS We performed a comprehensive search the Cochrane Library, MEDLINE, Embase, three other databases, trials registries, other sources of grey literature, and conference proceedings with no restrictions on language of publication or publication status, up to 8 November 2021. SELECTION CRITERIA We included parallel-group randomized controlled trials (RCTs), as well as non-randomized studies (NRS, limited to prospective cohort studies with concurrent comparison groups) enrolling men over the age of 40 years with LUTS attributed to BPH undergoing PAE versus TURP or other surgical interventions. DATA COLLECTION AND ANALYSIS: Two review authors independently classified studies for inclusion or exclusion and abstracted data from the included studies. We performed statistical analyses by using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. MAIN RESULTS: We found data to inform two comparisons: PAE versus TURP (six RCTs and two NRSs), and PAE versus sham (one RCT). Mean age was 66 years, International Prostate Symptom Score (IPSS) was 22.8, and prostate volume of participants was 72.8 mL. This abstract focuses on the comparison of PAE versus TURP as the primary topic of interest. Prostatic arterial embolization versus transurethral resection of the prostate We included six RCTs and two NRSs with short-term (up to 12 months) follow-up, and two RCTs and one NRS with long-term follow-up (13 to 24 months). Short-term follow-up: based on RCT evidence, there may be little to no difference in urologic symptom score improvement measured by the International Prostatic Symptom Score (IPSS) on a scale from 0 to 35, with higher scores indicating worse symptoms (mean difference [MD] 1.72, 95% confidence interval [CI] -0.37 to 3.81; 6 RCTs, 360 participants; I² = 78%; low-certainty evidence). There may be little to no difference in quality of life as measured by the IPSS-quality of life question on a scale from 0 to 6, with higher scores indicating worse quality of life between PAE and TURP, respectively (MD 0.28, 95% CI -0.28 to 0.84; 5 RCTs, 300 participants; I² = 63%; low-certainty evidence). While we are very uncertain about the effects of PAE on major adverse events (risk ratio [RR] 0.75, 95% CI 0.19 to 2.97; 4 RCTs, 250 participants; I² = 24%; very low-certainty evidence), PAE likely increases retreatments (RR 3.20, 95% CI 1.41 to 7.27; 4 RCTs, 303 participants; I² = 0%; moderate-certainty evidence). PAE may make little to no difference in erectile function measured by the International Index of Erectile Function-5 on a scale from 1 to 25, with higher scores indicating better function (MD -0.50 points, 95% CI -5.88 to 4.88; 2 RCTs, 120 participants; I² = 68%; low-certainty evidence). Based on NRS evidence, PAE may reduce the occurrence of ejaculatory disorders (RR 0.51, 95% CI 0.35 to 0.73; 1 NRS, 260 participants; low-certainty evidence). Long-term follow-up: based on RCT evidence, PAE may result in little to no difference in urologic symptom scores (MD 2.58 points, 95% CI -1.54 to 6.71; 2 RCTs, 176 participants; I² = 73%; low-certainty evidence) and quality of life (MD 0.50 points, 95% CI -0.03 to 1.04; 2 RCTs, 176 participants; I² = 29%; low-certainty evidence). We are very uncertain about major adverse events (RR 0.91, 95% CI 0.20 to 4.05; 2 RCTs, 206 participants; I² = 72%; very low-certainty evidence). PAE likely increases retreatments (RR 3.80, 95% CI 1.32 to 10.93; 1 RCT, 81 participants; moderate-certainty evidence). While PAE may result in little to no difference in erectile function (MD 3.09 points, 95% CI -0.76 to 6.94; 1 RCT, 81 participants; low-certainty evidence), PAE may reduce the occurrence of ejaculatory disorders (RR 0.67, 95% CI 0.45 to 0.98; 1 RCT, 50 participants; low-certainty evidence). AUTHORS' CONCLUSIONS Compared to TURP, PAE may provide similar improvement in urologic symptom scores and quality of life. While we are very uncertain about major adverse events, PAE likely increases retreatment rates. While erectile function may be similar, PAE may reduce ejaculatory disorders. Certainty of evidence for the outcomes of this review was low or very low except for retreatment (moderate-certainty evidence), signaling that our confidence in the reported effect size is limited or very limited, and that this topic should be better informed by future research.
Collapse
Affiliation(s)
- Jae Hung Jung
- Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea, South
- Center of Evidence-Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Korea, South
| | | | - Michael Borofsky
- Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
| | - Shamar Young
- Department of Radiology, Division of Interventional Radiology & Vascular Imaging, University of Minnesota, Minneapolis, Minnesota, USA
| | - Jafar Golzarian
- Department of Radiology, Division of Interventional Radiology & Vascular Imaging, University of Minnesota, Minneapolis, Minnesota, USA
| | - Myung Ha Kim
- Yonsei Wonju Medical Library, Yonsei University Wonju College of Medicine, Wonju, Korea, South
| | - Vikram M Narayan
- Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
| | - Philipp Dahm
- Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
- Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA
| |
Collapse
|
|
33
|
McClure TD, Ortiz AK, Doustaly R, Rocha A, Moreira AM, de Assis AM, Barral M, Cornelis FH, Carnevale FC. Use of Virtual Injection Technology for Planning and Guidance of Prostate Artery Embolization. Cardiovasc Intervent Radiol 2022; 45:884-887. [PMID: 35149885 DOI: 10.1007/s00270-022-03068-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 01/25/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Timothy D McClure
- Department of Radiology, Division of Interventional Radiology, Weill Cornell Medicine, 525 East 68th Street, New York, NY, 10065, USA.
| | - Ana K Ortiz
- Department of Radiology, Division of Interventional Radiology, Weill Cornell Medicine, 525 East 68th Street, New York, NY, 10065, USA
| | | | - Arthur Rocha
- Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, Sao Paulo, 25505403-000, Brazil
| | - Airton M Moreira
- Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, Sao Paulo, 25505403-000, Brazil
| | - Andre M de Assis
- Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, Sao Paulo, 25505403-000, Brazil
| | - Matthias Barral
- Department of Interventional Radiology and Oncology, Sorbonne University, Tenon Hospital, 4 Rue de la Chine, 75020, Paris, France
| | - Francois H Cornelis
- Department of Interventional Radiology and Oncology, Sorbonne University, Tenon Hospital, 4 Rue de la Chine, 75020, Paris, France
| | - Francisco C Carnevale
- Interventional Radiology Department, Radiology Institute, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, Sao Paulo, 25505403-000, Brazil
| |
Collapse
|
|
34
|
Bilhim T, Costa NV, Torres D. Prostatic Artery Embolization for Benign Prostatic Hyperplasia—A Primer for Interventional Radiologists. THE ARAB JOURNAL OF INTERVENTIONAL RADIOLOGY 2022. [DOI: 10.1055/s-0041-1739302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
AbstractMale patients over 50 years with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are potential candidates for prostatic artery embolization (PAE). PAE is not a perfect fit for all BPH patients. Careful pre- and postpostprocedural evaluation/consultation with correct selection of patients should be tailored on an individual basis. Evaluated parameters include the following: LUTS severity quantification with validated questionnaires as the international prostate symptom score (IPSS) and quality of life (QoL), erectile and ejaculatory evaluation with validated questionnaires, blood tests including full blood count, coagulation profile, renal function and total/free prostate-specific antigen (PSA), prostate volume measured by multiparametric magnetic resonance (mpMR) of the prostate and/or transrectal ultrasound, uroflowmetry measuring the peak urinary flowrate (Qmax), and postvoid residual urine (PVR). Correct arterial anatomy identification with either computed tomography (CT) angiography, MR angiography, or intraprocedural cone-beam CT (CBCT) are suggested for a confident procedure and avoiding potential complications. The minimally invasive nature of PAE with a faster recovery, preserving the sexual function, and comparable results to standard prostatic surgery make the procedure an attractive choice for many male patients suffering with this condition. Patients should be informed about the potential for higher retreatment rates and shorter duration of treatment effect when compared with standard prostatic surgery. In this comprehensive review, we provide an updated toolbox for all interventional radiologists interested in the PAE practice for patients with BPH. We explain how to evaluate patients during consultation before and after PAE, describe the preprocedural imaging required, explain the technique, and narrate how to optimize outcomes. Finally, we review the level of evidence of PAE for BPH.
Collapse
Affiliation(s)
- Tiago Bilhim
- Angiography Unit, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Saint Louis Hospital, Portugal and Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| | - Nuno V. Costa
- Angiography Unit, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Saint Louis Hospital, Portugal and Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| | - Daniel Torres
- Angiography Unit, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Saint Louis Hospital, Portugal and Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
| |
Collapse
|
|
35
|
Pilan BF, Assis AMD, Moreira AM, Rodrigues VCDP, Carnevale FC. Protection of nontarget structures in prostatic artery embolization. Radiol Bras 2022; 55:6-12. [PMID: 35210658 PMCID: PMC8864683 DOI: 10.1590/0100-3984.2021.0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 03/16/2021] [Indexed: 11/24/2022] Open
Abstract
Objective To describe the efficacy and safety of protective embolization during prostatic artery
embolization, as well as to discuss its clinical relevance. Materials and Methods This was a retrospective, observational, single-center study including 39 patients who
underwent prostatic artery embolization to treat lower urinary tract symptoms related to
benign prostatic hyperplasia between June 2008 and March 2018. Follow-up evaluations,
performed at 3 and 12 months after the procedure, included determination of the International
Prostate Symptom Score, a quality of life score, and prostate-specific antigen levels, as well
as ultrasound, magnetic resonance imaging, and uroflowmetry. Results Protective embolization was performed in 45 arteries: in the middle rectal artery in 19
(42.2%); in the accessory internal pudendal artery in 11 (24.4%); in an internal pudendal
artery anastomosis in 10 (22.2%); in the superior vesical artery in four (8.9%); and in the
obturator artery in one (2.2%). There was one case of nontarget embolization leading to a
penile ulcer, which was attributed to reflux of microspheres to an unprotected artery. There
were no complications related to the protected branches. All of the patients showed
significant improvement in all of the outcomes studied (p < 0.05), and
none reported worsening of sexual function during follow-up. Conclusion Protective embolization can reduce nontarget embolization during prostatic artery
embolization without affecting the results of the procedure. In addition, no adverse events
other than those expected or previously reported were observed. Therefore, protective
embolization of pudendal region is safe.
Collapse
|
|
36
|
Bilhim T, Betschart P, Lyatoshinsky P, Müllhaupt G, Abt D. Minimally Invasive Therapies for Benign Prostatic Obstruction: A Review of Currently Available Techniques Including Prostatic Artery Embolization, Water Vapor Thermal Therapy, Prostatic Urethral Lift, Temporary Implantable Nitinol Device and Aquablation. Cardiovasc Intervent Radiol 2022; 45:415-424. [DOI: 10.1007/s00270-021-03052-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Accepted: 12/21/2021] [Indexed: 02/06/2023]
|
|
37
|
Minimally Invasive Treatments for Benign Prostatic Hyperplasia: Systematic Review and Network Meta-Analysis. J Vasc Interv Radiol 2021; 33:359-367.e8. [PMID: 34968671 DOI: 10.1016/j.jvir.2021.12.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 09/30/2021] [Accepted: 12/16/2021] [Indexed: 11/23/2022] Open
Abstract
PURPOSE To review and indirectly compare the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. MATERIALS AND METHODS A literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostate artery embolization (PAE). Data on the following variables were included: international Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), quality of life (QoL), and post-void residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect. RESULTS No significant difference in outcomes between therapies were noted for IPSS at the 3-, 6-, and 12-month follow-ups. Although outcomes for rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation vs PAE vs Rezum. TURP PVR was significantly better than Urolift at 3-, 6-, and 12 months. No significant differences in minor or major AEs were noted. CONCLUSION Although significant differences in outcomes were limited, aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while aquablation has limited high quality data and has been associated with bleeding-related complications.
Collapse
|
|
38
|
Hakimé A, Tun JK, Haab F, Sarrazin JL, De Baere T, Tselikas L, Kuoch V. Using prostate contrast retention (PCR) as the procedural endpoint in prostatic artery embolization for benign prostatic hyperplasia. Eur Radiol 2021; 31:9150-9160. [PMID: 34050801 DOI: 10.1007/s00330-021-08063-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 05/07/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The failure rate following prostate artery embolization (PAE) is around 20%, which may in part result from inadequate embolization. Prostate contrast retention (PCR) adequacy on immediate post-embolization cone-beam CT may provide better assessment of embolization completeness than arterial contrast stasis seen on fluoroscopy alone. The aim of this study was to evaluate outcomes of PAE using PCR adequacy as the procedural endpoint. METHODS A retrospective cohort study of all PAE cases using this technique at a single large volume center was conducted. Following initial embolization of the main prostatic arteries, if PCR was inadequate, additional embolization was performed. Technical success (adequate PCR) was defined as > 75% global prostate gland contrast staining. Clinical success was determined in accordance to CIRSE standards of practice. RESULTS One hundred sixty-five patients (mean age 68 ± 8.4 years) underwent PAE from June 2017 to March 2019. Technical and clinical success rates were 98.8% and 96.4% respectively. Clinical success rate was significantly higher in patients with adequate PCR. International Prostate Symptom Scores (IPSS) and Quality of Life (QoL) scores significantly improved at 1-, 3-, 6-, and 12-month follow-up when compared to baseline. Prostate volume (PV) and post-voiding residual bladder volume were significantly reduced at 3, 6, and 12 months in comparison to baseline. Mild (Clavien-Dindo grade I/II) and moderate (grade III) complication rates were 12.1% and 3.6% respectively. CONCLUSIONS By using PCR adequacy as a guide to determine the procedure endpoint for PAE, it may be possible to achieve more complete embolization and thus higher clinical success rates. KEY POINTS • By using PCR adequacy as a guide to determine the procedure endpoint for PAE, it may be possible to achieve more complete embolization and thus higher clinical success rates.
Collapse
Affiliation(s)
- Antoine Hakimé
- Department of Interventional Radiology, American Hospital of Paris, Neuilly-sur-Seine, Paris, France.
- Department of Radiology, Hôpital Sud Francilien, Corbeil-Essonnes, France.
| | - Jimmy Kyaw Tun
- Department of Interventional Radiology, The Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK
| | - François Haab
- Department of Urology, American Hospital of Paris, Neuilly-sur-Seine, Paris, France
| | - Jean Luc Sarrazin
- Department of Interventional Radiology, American Hospital of Paris, Neuilly-sur-Seine, Paris, France
| | - Thierry De Baere
- Department of Surgical Radiology, Institut Gustave Roussy, Villejuif, France
| | - Lambros Tselikas
- Department of Surgical Radiology, Institut Gustave Roussy, Villejuif, France
| | - Viseth Kuoch
- Department of Radiology, Hôpital Sud Francilien, Corbeil-Essonnes, France
| |
Collapse
|
|
39
|
Unwala DJ. EDITORIAL COMMENT. Urology 2021; 156:223. [PMID: 34758560 DOI: 10.1016/j.urology.2021.02.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Accepted: 02/18/2021] [Indexed: 11/16/2022]
Affiliation(s)
- Darius J Unwala
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH
| |
Collapse
|
|
40
|
Vogl TJ, Zinn A, Elhawash E, Alizadeh LS, Nour-Eldin NEA, Naguib NNN. MR angiography-planned prostatic artery embolization for benign prostatic hyperplasia: single-center retrospective study in 56 patients. Diagn Interv Radiol 2021; 27:725-731. [PMID: 34792026 PMCID: PMC8621648 DOI: 10.5152/dir.2021.20124] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 09/17/2020] [Accepted: 10/08/2020] [Indexed: 11/22/2022]
Abstract
PURPOSE We aimed to evaluate the advantages of magnetic resonance angiography (MRA)-planned prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH). METHODS In this retrospective study, MRAs of 56 patients (mean age, 67.23±7.73 years; age range, 47-82 years) who underwent PAE between 2017 and 2018 were evaluated. For inclusion, full information about procedure time and radiation values must have been available. To identify prostatic artery (PA) origin, three-dimensional MRA reconstruction with maximum intensity projection was conducted in every patient. In total, 33 patients completed clinical and imaging follow-up and were included in clinical evaluation. RESULTS There were 131 PAs with a second PA in 19 pelvic sides. PA origin was correctly identified via MRA in 108 of 131 PAs (82.44%). In patients in which MRA allowed a PA analysis, a significant reduction of the fluoroscopy time (-27.0%, p = 0.028) and of the dose area product (-38.0%, p = 0.003) was detected versus those with no PA analysis prior to PAE. Intervention time was reduced by 13.2%, (p = 0.25). Mean fluoroscopy time was 30.1 min, mean dose area product 27,749 µGy•m2, and mean entrance dose 1553 mGy. Technical success was achieved in all 56 patients (100.0%); all patients were embolized on both pelvic sides. The evaluated data documented a significant reduction in IPSS (p < 0.001; mean 9.67 points). CONCLUSION MRA prior to PAE allowed the identification of PA in 82.44% of the cases. MRA-planned PAE is an effective treatment for patients with BPH.
Collapse
Affiliation(s)
- Thomas J. Vogl
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| | - Annette Zinn
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| | - Elsayed Elhawash
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| | - Leona S. Alizadeh
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| | - Nour-Eldin A. Nour-Eldin
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| | - Nagy N. N. Naguib
- From Institute of Diagnostic and Interventional Radiology (T.J.V. , A.Z., E.E., L.S.A., N.A.N), University Hospital Frankfurt, Frankfurt, Germany; Department of Diagnostic and Interventional Radiology (N.A.N.), Cairo University Hospital, Cairo, Egypt; Department of Radiology (N.N.N.N.), AMEOS Hospital Halberstadt, Halberstadt, Germany; Department of Diagnostic and Interventional Radiology (N.N.N.N.), Alexandria University Hospital, Alexandria, Egypt
| |
Collapse
|
|
41
|
Prostate Artery Embolization-Review of Indications, Patient Selection, Techniques and Results. J Clin Med 2021; 10:jcm10215139. [PMID: 34768659 PMCID: PMC8584630 DOI: 10.3390/jcm10215139] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 10/27/2021] [Accepted: 10/29/2021] [Indexed: 12/28/2022] Open
Abstract
Lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) are a very common problem in men ranging from mild urinary symptoms to recurrent urinary tract infections or renal failure. Numerous treatment options are available ranging from conservative medical therapies to more invasive surgical options. Prostate artery embolization (PAE) has emerged as a novel treatment option for this common problem with clinical efficacy comparable to the current surgical gold standard, transurethral resection of the prostate (TURP). PAE offers fewer complications and side effects without a need for general anesthesia or hospitalization. This review discusses the indications for prostate artery embolization in addition to LUTS, patient evaluation in patients with LUTS, PAE technique and clinical results, with an emphasis on efficacy and safety.
Collapse
|
|
42
|
Dias US, de Moura MRL, Viana PCC, de Assis AM, Marcelino ASZ, Moreira AM, Leite CC, Cerri GG, Carnevale FC, Horvat N. Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications. Radiographics 2021; 41:1509-1530. [PMID: 34415807 DOI: 10.1148/rg.2021200144] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Benign prostatic hyperplasia (BPH) is a noncancerous growth of the transitional zone of the prostate, which surrounds the prostatic urethra. Consequently, it can cause lower urinary tract symptoms (LUTS) and bladder outlet obstruction symptoms that may substantially reduce a patient's quality of life. Several treatments are available for BPH, including medications such as α-blockers and 5α-reductase inhibitors and surgical options including transurethral resection of the prostate and prostatectomy. Recently, prostatic artery embolization (PAE) has emerged as a minimally invasive treatment option for selected men with BPH and moderate to severe LUTS. Adequate pre- and postprocedural evaluations with clinical examinations and questionnaires, laboratory tests, and urodynamic and imaging examinations (particularly US, MRI, and CT) are of key importance to achieve successful treatment. Considering that the use of PAE has been increasing in tertiary hospital facilities, radiologists and interventional radiologists should be aware of the main technical concepts of PAE and the key features to address in imaging reports in pre- and postprocedural settings. An invited commentary by Lopera is available online. Online supplemental material is available for this article. ©RSNA, 2021.
Collapse
Affiliation(s)
- Ubenicio Silveira Dias
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Maurício Ruettimann Liberato de Moura
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Publio Cesar Cavalcante Viana
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - André Moreira de Assis
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Antônio Sérgio Zanfred Marcelino
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Airton Mota Moreira
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Claudia Costa Leite
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Giovanni Guido Cerri
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Francisco Cesar Carnevale
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| | - Natally Horvat
- From the Departments of Radiology (U.S.D., M.R.L.d.M., P.C.C.V., A.S.Z.M., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), Hospital Sírio-Libanês, Adma Jafet 91, Bela Vista, São Paulo, SP 01308-050, Brazil; Departments of Radiology (M.R.L.d.M., P.C.C.V., C.C.L., G.G.C.) and Interventional Radiology (M.R.L.d.M., P.C.C.V., A.M.d.A., A.M.M., F.C.C.), University of São Paulo, São Paulo, Brazil; and Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY (N.H.)
| |
Collapse
|
|
43
|
Role of Ultrasound Elastography in Patient Selection for Prostatic Artery Embolization. J Vasc Interv Radiol 2021; 32:1410-1416. [PMID: 34333109 DOI: 10.1016/j.jvir.2021.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 07/03/2021] [Accepted: 07/18/2021] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the effects of prostatic artery embolization (PAE) on prostate elasticity as assessed using ultrasound elastography (US-E) and to describe baseline US-E's potential role in patient selection. MATERIALS AND METHODS This was a prospective investigation that included 20 patients undergoing PAE to treat lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). US-E with measurement of the prostatic elastic modulus (EM) and shear wave velocity (SWV) was performed before PAE and at 1-month follow-up. Baseline, 3-month, and 1-year follow-up evaluations included prostate-specific antigen, uroflowmetry, pelvic magnetic resonance imaging, and clinical assessment using the International Prostate Symptom Score (IPSS) and quality of life (QoL) metrics. RESULTS Seventeen patients entered statistical analysis. US-E showed a significant reduction in mean prostatic EM (34.4 kPa vs 46.3 kPa, -24.7%, P < .0001) and SWV (3.55 m/s vs 4.46 m/s, -20.0%, P < .0001) after PAE. There were moderate positive correlations between baseline EM and 1-year IPSS (R = 0.62, P = .007) and between baseline SWV and 1-year IPSS (R = 0.68, P = .002). Baseline SWV ≥ 5.59 m/s and baseline EM ≥ 50.14 kPa were associated with suboptimal IPSS and QoL outcomes after PAE with high degrees of sensitivity (100%) and specificity (69-100%). CONCLUSIONS PAE led to a positive effect on the BPH dynamic component related to prostatic elasticity. There was a moderate positive correlation between baseline prostatic elastographic parameters and 12-month IPSS. Measurement of baseline elastographic characteristics may become useful for the evaluation and selection of patients for PAE.
Collapse
|
|
44
|
LaRussa S, Pantuck M, Wilcox Vanden Berg R, Gaffney CD, Askin G, McClure T. Symptomatic Improvement of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Comparative Systematic Review and Meta-Analysis of 4 Different Minimally Invasive Therapies. J Vasc Interv Radiol 2021; 32:1328-1340.e11. [PMID: 34256123 DOI: 10.1016/j.jvir.2021.06.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 05/27/2021] [Accepted: 06/22/2021] [Indexed: 11/28/2022] Open
Abstract
PURPOSE To review and compare the outcomes of prostatic artery embolization (PAE) with 3 other minimally invasive surgical treatments for benign prostatic hyperplasia, including photoselective vaporization (PVP), prostatic urethral lift (PUL), and water vapor thermal therapy (WV). METHODS A literature review was used to identify 35 publications, which included 2,653 patients (studies, patients): PVP (13, 949), PUL (9, 577), WV (3, 330), and PAE (10, 728). The international prostate symptom score (IPSS) and the international index of erectile function (IIEF-5) and quality of life (QOL) scores were recorded at baseline, 6 months, and 12 months. Meta-analyses, pooling the standardized mean difference between scores recorded before and after treatment, were conducted for each modality and time point to assess the magnitude of a therapy's effect to yield pooled effect sizes. A negative score indicates IPSS and QOL improvement. A positive score indicates IIEF-5 improvement. RESULTS At 6 and 12 months, the IPSS and QOL were most improved after PVP, followed by that after PAE, PUL, and, lastly, WV (measured only at 12 months). Between 6 and 12 months, the IPSS and QOL improved with PAE and worsened with PVP and PUL. Only PAE demonstrated statistical improvement in the IIEF-5, which improved from 6 to 12 months. CONCLUSIONS PVP and PAE resulted in the largest improvements in the IPSS and QOL. Only PAE resulted in improvement of the IIEF-5.
Collapse
Affiliation(s)
- Samuel LaRussa
- Department of Interventional Radiology, Weill Cornell Medicine/New York Presbyterian, New York, New York; Department of Radiology, Einstein-Jacobi Medical Center, Bronx, New York
| | - Morgan Pantuck
- Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania
| | | | | | - Gulce Askin
- Division of Biostatistics, Department of Population Health Sciences, and Weill Cornell Medicine, New York, New York
| | - Timothy McClure
- Department of Interventional Radiology, Weill Cornell Medicine/New York Presbyterian, New York, New York; Department of Urology, Weill Cornell Medicine/New York Presbyterian, New York, New York.
| |
Collapse
|
|
45
|
Shaker M, Hashem E, Abdelrahman A, Okba A. Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Anatomical Aspects and Radiation Considerations from a Case Series of 210 Patients. THE ARAB JOURNAL OF INTERVENTIONAL RADIOLOGY 2021. [DOI: 10.1055/s-0041-1729134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Abstract
Context Prostatic artery embolization (PAE) has been established as a safe and effective treatment option for symptomatic benign prostatic hyperplasia (BPH). Thorough knowledge of detailed prostatic artery (PA) anatomy is essential.
Aims The aim of this study was to provide a pictorial review of PA anatomy and prevalence of related anatomical variants, in addition to other anatomical and radiation dose considerations.
Settings and Design Case series and review of literature.
Materials and Methods We performed PAE for 210 patients from November 2015 to November 2020 under local anesthesia only. Anatomy, procedure duration, fluoroscopy time, radiation dose, technical success, and complications were analyzed.
Statistical Analysis Used Descriptive statistics were analyzed using Microsoft Excel software.
Results A total of 210 patients (420 sides) were analyzed. Double arterial supply on the same side was noted in 12 patients (5.7%). In 10 patients (4.7%), only a unilateral PA was identified. In two patients (0.9%), no PA could be identified. Frequencies of PA origins were calculated. Penile, rectal, and vesical anastomoses were identified with 79 (18.8%), 54 (12.9%), and 41 (9.8%) of PAs, respectively. Median skin radiation dose, procedure time, and fluoroscopy time were 505 mGy, 73 and 38 minutes, respectively. Complications occurred in nine patients (4.3%), none of them was major.
Conclusions Knowledge of PA anatomy is essential when treating BPH by PAE for optimum results. There is no enough evidence to support routine use of preoperative computed tomography angiography and intraoperative cone-beam computed tomography as means of improving safety or efficacy.
Collapse
Affiliation(s)
- Mohamed Shaker
- Department of Diagnostic and Interventional Radiology, Ain Shams University, Cairo, Egypt
| | - Essam Hashem
- Department of Department of Diagnostic and Interventional Radiology, Ain Shams University, King’s College Hospital, Cairo, Egypt
| | | | - Ahmed Okba
- Department of Diagnostic and Interventional Radiology, Ain Shams University, Cairo, Egypt
| |
Collapse
|
|
46
|
Dariushnia SR, Redstone EA, Heran MKS, Cramer HR, Ganguli S, Gomes AS, Hogan MJ, Himes EA, Patel S, Schiro BJ, Lewis CA. Society of Interventional Radiology Quality Improvement Standards for Percutaneous Transcatheter Embolization. J Vasc Interv Radiol 2021; 32:476.e1-476.e33. [PMID: 33640083 DOI: 10.1016/j.jvir.2020.10.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 10/22/2020] [Indexed: 01/14/2023] Open
Affiliation(s)
- Sean R Dariushnia
- Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image-Guided Medicine, Emory University School of Medicine, Grady Memorial Hospital, 80 Jesse Hill Dr, SE, Atlanta, GA, 30303.
| | - Ellen A Redstone
- Department of Interventional Radiology, St. Luke's University Health Network, 801 Ostrum St., Bethlehem, PA, 18015
| | - Manraj K S Heran
- Pediatric Interventional Radiology, Diagnostic & Therapeutic Neuroradiology, British Columbia's Children's Hospital, Vancouver General Hospital, University of British Columbia, 899 West 12th Avenue, Vancouver, BC, Canada
| | - Harry R Cramer
- Section of Interventional Radiology, Coastal Vascular and Interventional, PLLC, 3155 Hyde Park Place, Pensacola, FL, 32503
| | - Suvranu Ganguli
- Department of Radiology, Division of Interventional Radiology, Boston Medical Center, Boston University School of Medicine, 820 Harrison Avenue, FGH 4th Floor, Boston, MA, 02118
| | - Antoinette S Gomes
- Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, 757 Westwood Plz Ste 2125, Los Angeles, CA, 90095-8358
| | - Mark J Hogan
- Department of Radiology, Section of Vascular and Interventional Radiology, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205
| | - Elizabeth A Himes
- Society of Interventional Radiology, 3975 Fair Ridge Drive, Suite 400 North, Fairfax, VA, 22033
| | - Sheena Patel
- Society of Interventional Radiology, 3975 Fair Ridge Drive, Suite 400 North, Fairfax, VA, 22033
| | - Brian J Schiro
- Department of Vascular & Interventional Radiology, Miami Cardiac & Vascular Institute, 8900 N. Kendall Drive, Miami, FL, 33156, United States
| | - Curtis A Lewis
- Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image-Guided Medicine, Emory University School of Medicine, Grady Memorial Hospital, 80 Jesse Hill Dr, SE, Atlanta, GA, 30303
| |
Collapse
|
|
47
|
Safety and efficacy of holmium laser enucleation of prostate as salvage procedure for persistent or recurrent lower urinary tract symptoms secondary to bladder outlet obstruction after prior prostate artery embolization: a match analysis. World J Urol 2021; 39:4199-4206. [PMID: 34081181 DOI: 10.1007/s00345-021-03747-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 05/25/2021] [Indexed: 10/21/2022] Open
Abstract
PURPOSE To evaluate safety and efficacy of Holmium laser enucleation of Prostate (HoLEP) for management of persistent or recurrent lower urinary tract symptoms after prior prostate artery embolization (PAE). We also evaluated histopathological changes in prostate after PAE. METHODS Ten patients who underwent HoLEP after prior PAE were matched according to age, weight of resected prostate tissue, and anticoagulation status in 1:2 ratio with patients who underwent HoLEP without prior PAE by a researcher who was blinded to patient's outcome at the time of matching. Histopathological examination of prostate tissue was performed to look for changes related to prior PAE. Patient's demographics, perioperative parameters, and follow-up data were retrospectively compared. RESULTS The median interval between PAE and HoLEP was 25 months [IQR 14.5-37.5]. Patients demographic were comparable in both groups. Intra-operatively plane of enucleation were well-maintained in spite of prior PAE. The differences in duration of surgery, enucleation efficiency, hemoglobin drop, duration of catheterization and hospital stay, and complications were statistically insignificant. Incidental prostate cancer was identified in 10% specimens from both groups. Post-PAE prostate specimens demonstrated evidence of remote-healed infarction represented by dense hyalinized paucicellur connective tissue with surrounding squamous metaplasia. There were no statistically significant differences in AUA symptom scores, maximum urine flow rate, post-void residual urine volume, and PSA at 3- and 6-month follow-up between both groups. CONCLUSIONS Plane of enucleation is well-maintained after prior PAE. Salvage HoLEP is safe and effective after previous PAE and provide outcome comparable with HoLEP as a primary procedure.
Collapse
|
|
48
|
Sare A, Kothari P, Cieslak JA, Gantz O, Aly S, Kumar A, Patel N, Shukla PA. Perioperative Blood Loss after Preoperative Prostatic Artery Embolization in Patients Undergoing Simple Prostatectomy: A Propensity Score‒Matched Study. J Vasc Interv Radiol 2021; 32:1113-1118. [PMID: 34062272 DOI: 10.1016/j.jvir.2021.05.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 04/26/2021] [Accepted: 05/19/2021] [Indexed: 11/19/2022] Open
Abstract
PURPOSE To assess perioperative blood loss following prostatic artery embolization (PAE) before surgery in patients undergoing simple prostatectomy. METHODS A retrospective chart review was used to identify 63 patients (mean age, 65.3 ± 8.0 years) with prostatic hypertrophy and severe lower urinary tract symptoms who underwent prostatectomy from September 2014 to December 2019, 18 (28.5%) of whom underwent PAE before surgery. Demographic data, pertinent laboratory results, procedural or operative information, hospital course details, and pathology reports were obtained. A 2:1 propensity score‒matching analysis was performed to compare intraoperative blood loss in patients who underwent prostatectomy alone with intraoperative blood loss in those who first underwent bilateral PAE before surgery. RESULTS Sixteen (89%) of the 18 patients underwent bilateral PAE before surgery. Thirty-two patients who underwent prostatectomy without embolization before surgery were selected for the 2:1 propensity score‒matched analysis based on age, race, surgery type, prostate gland size, and comorbidities. The mean estimated blood loss (EBL) for prostatectomy alone was 545 ± 380 mL (mean ± standard deviation). There was a statistically significant reduction in the EBL for patients who underwent bilateral PAE (303 ± 227 mL, P < .01). The operative time was also significantly decreased for patients who underwent PAE before surgery (P < .05). For patients who underwent PAE, there were no complications related to the procedure. CONCLUSIONS Bilateral PAE before surgery appears to be safe and may be effective in reducing perioperative bleeding and operative time.
Collapse
Affiliation(s)
- Antony Sare
- Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Pankti Kothari
- Division of Urology, Department of Surgery, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - John A Cieslak
- Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Owen Gantz
- Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Samuel Aly
- Division of Urology, Department of Surgery, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Abhishek Kumar
- Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Nitin Patel
- Division of Urology, Department of Surgery, Rutgers - New Jersey Medical School, Newark, New Jersey
| | - Pratik A Shukla
- Division of Vascular and Interventional Radiology, Department of Radiology, Rutgers - New Jersey Medical School, Newark, New Jersey.
| |
Collapse
|
|
49
|
Voiding and Storage Domain-Specific Symptom Score Outcomes After Prostate Artery Embolization for Lower Urinary Tract Symptoms and Urinary Retention. Urology 2021; 156:216-224. [PMID: 33961894 DOI: 10.1016/j.urology.2021.02.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 01/28/2021] [Accepted: 02/18/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To characterize voiding and storage symptom domain-specific outcomes after prostate artery embolization (PAE) to treat lower urinary tract symptoms (LUTS) or urinary retention caused by benign prostatic hyperplasia (BPH). METHODS Two hundred forty patients (age = 74.5 ± 8.6 years) underwent PAE between May 2013 and March 2020 at a single center for LUTS (n = 161) or urinary retention (n = 79). Total International Prostate Symptom Score (IPSS-t), voiding domain score (IPSS-v), storage domain score (IPSS-s), and Quality of Life score (QoL) were obtained pre-PAE for LUTS patients (IPSS-t = 21.7 ± 6.2, IPSS-v = 11.9 ± 4.3, IPSS-s = 9.6 ± 3.1, QoL = 4.5 ± 1.2), and post-PAE through 36 months (mean = 22.9 ± 15.2 months) for LUTS and retention patients. Mean relative changes in IPSS-t, IPSS-v, IPSS-s, and QoL were calculated for LUTS patients. Mean voiding or storage component scores were calculated for retention patients. RESULTS For evaluable LUTS patients (n = 147), IPSS-t showed sustained substantial improvement through 36 months (6.3 ± 4.2-8.6 ± 7.6), as did QoL (1.1 ± 1.1-1.8 ± 1.5). One month after PAE, improvements in IPSS-v (69% ± 29%) were greater than in IPSS-s (46% ± 33%; P < .000001), and remained so through 36 months (68% ± 31% vs 53% ± 28%, P = .004). Among evaluable retention patients (n = 75), 84% passed voiding trials. Both IPSS-t (6.0 ± 3.9-8.2 ± 6.7) and QoL (0.9 ± 1.2-1.5 ± 1.6) remained low through 36 months. One month after PAE, mean IPSS-v component score (0.9 ± 1.3) was lower than mean IPSS-s component score (1.7 ± 1.4; P = .003) and remained so through 24 months (0.9 ± 1.2 vs 1.3 ± 1.1, P = .02), with similar trend at 36 months (0.7 ± 1.1 vs 1.1 ± 1.1, P = .07). CONCLUSIONS PAE effectively treated BPH-related LUTS and retention. IPSS-v improved more than IPSS-s in LUTS patients, and remained lower in LUTS and retention patients through 36 months.
Collapse
|
|
50
|
Vigneswaran G, Maclean D, Hadi M, Maher B, Modi S, Bryant T, Harris M, Hacking N. Prostatic Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) have a Differential Impact on Lower Urinary Tract Symptoms (LUTS): Retrospective Analysis of the Multicentre UK-ROPE (UK Register of Prostate Embolization) Study. Cardiovasc Intervent Radiol 2021; 44:1095-1102. [PMID: 33825062 PMCID: PMC8189939 DOI: 10.1007/s00270-021-02821-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 03/03/2021] [Indexed: 10/27/2022]
Abstract
PURPOSE To compare the relative IPSS (International Prostate Symptom Score) improvement in storage and voiding symptoms between prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP). METHOD Retrospective analysis of the UK-ROPE (UK Register of Prostate Embolization) multicentre database was conducted with inclusion of all patients with full IPSS questionnaire score data. The voiding and storage subscore improvement was compared between interventions. Student's t-test (paired and unpaired) and ANOVA (Analysis of variance) were used to identify significant differences between the groups. RESULTS 146 patients (121 PAE, 25 TURP) were included in the analysis. Storage symptoms were more frequently the most severe symptom ('storage' in 75 patients vs 'voiding' in 17 patients). Between groups, no significant difference was seen in raw storage subscore improvement (TURP 4.9 vs PAE 4.2; p = 0.34) or voiding subscore improvement (TURP 8.4 vs PAE 6.7; p = 0.1). ANOVA demonstrated a greater proportionate reduction (relative to total IPSS) towards voiding symptoms in the TURP group (27.3% TURP vs 9.9% PAE, p = 0.001). CONCLUSION Although both TURP and PAE improve voiding symptoms more than storage, a significantly larger proportion of total symptom reduction is due to voiding in the TURP cohort, with PAE providing a more balanced improvement between voiding and storage.
Collapse
Affiliation(s)
- Ganesh Vigneswaran
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK. .,Cancer Sciences, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK.
| | - Drew Maclean
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Mohammed Hadi
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Benjamin Maher
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Sachin Modi
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Timothy Bryant
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Mark Harris
- Department of Urology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Nigel Hacking
- Department of Interventional Radiology, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK
| |
Collapse
|